1
|
El-Khoueiry AB, Trojan J, Meyer T, Yau T, Melero I, Kudo M, Hsu C, Kim TY, Choo SP, Kang YK, Yeo W, Chopra A, Soleymani S, Yao J, Neely J, Tschaika M, Welling TH, Sangro B. Nivolumab in sorafenib-naive and sorafenib-experienced patients with advanced hepatocellular carcinoma: 5-year follow-up from CheckMate 040. Ann Oncol 2024; 35:381-391. [PMID: 38151184 DOI: 10.1016/j.annonc.2023.12.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/30/2023] [Revised: 12/07/2023] [Accepted: 12/11/2023] [Indexed: 12/29/2023] Open
Abstract
BACKGROUND Patients with advanced hepatocellular carcinoma (aHCC) have a poor prognosis and high mortality. Nivolumab monotherapy demonstrated clinical benefit with an acceptable safety profile in patients with aHCC in the CheckMate 040 study. Five-year follow-up of the sorafenib-naive and sorafenib-experienced groups of CheckMate 040 is presented here. PATIENTS AND METHODS Patients received nivolumab monotherapy at dose levels of 0.1-10.0 mg/kg (dose-escalation phase) or 3 mg/kg (dose-expansion phase) every 2 weeks until disease progression or unacceptable toxicity. Primary endpoints were safety and tolerability (dose escalation), and objective response rate (ORR) by blinded independent central review (BICR) and by investigator as per RECIST version 1.1 (dose expansion). RESULTS Eighty sorafenib-naive and 154 sorafenib-experienced patients were treated. Minimum follow-up in both groups was 60 months. ORR as per BICR was 20% [95% confidence interval (CI) 12% to 30%] and 14% (95% CI 9% to 21%) in the sorafenib-naive and sorafenib-experienced groups, respectively. Responses occurred regardless of HCC etiology or baseline tumor cell programmed death-ligand 1 (PD-L1) expression levels. Median overall survival (OS) was 26.6 months (95% CI 16.6-30.6 months) and 15.1 months (95% CI 13.0-18.2 months) in sorafenib-naive and sorafenib-experienced patients, respectively. The 3-year OS rates were 28% in the sorafenib-naive and 20% in the sorafenib-experienced groups; 5-year OS rates were 14% and 12%, respectively. No new safety signals were identified; grade 3/4 treatment-related adverse events were observed in 33% and 21% of patients in the sorafenib-naive and sorafenib-experienced groups, respectively. Biomarker analyses showed that baseline PD-L1 expression ≥1% was associated with higher ORR and longer OS compared with PD-L1 <1%. In the sorafenib-naive group, patients with OS ≥3 years exhibited higher baseline CD8 T-cell density compared with those with OS <1 year. CONCLUSION With 5 years of follow-up, nivolumab monotherapy continued to provide durable clinical benefit with manageable safety in sorafenib-naive and sorafenib-experienced patients with aHCC.
Collapse
Affiliation(s)
- A B El-Khoueiry
- Division of Medical Oncology, USC Norris Comprehensive Cancer Center, Los Angeles, USA.
| | - J Trojan
- Department of Medicine, Goethe University Hospital and Cancer Center, Frankfurt, Germany
| | - T Meyer
- Department of Oncology, Royal Free Hospital, London, UK
| | - T Yau
- Department of Medicine, University of Hong Kong, Hong Kong, China
| | - I Melero
- Department of Immunology, Clinica Universidad de Navarra and CIBERONC, Pamplona, Spain
| | - M Kudo
- Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine, Osaka, Japan
| | - C Hsu
- Department of Medical Oncology, National Taiwan University Cancer Center, Taipei, Taiwan; Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan
| | - T-Y Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul, Korea
| | - S-P Choo
- Division of Medical Oncology, National Cancer Center and Curie Oncology, Singapore, Republic of Singapore
| | - Y-K Kang
- Department of Oncology, Asan Medical Center, University of Ulsan, Seoul, Korea
| | - W Yeo
- Department of Clinical Oncology, Chinese University of Hong Kong, Hong Kong, China
| | - A Chopra
- Department of Medical Oncology, Johns Hopkins Singapore International Medical Centre, Singapore, Republic of Singapore
| | - S Soleymani
- Global Biometrics & Data Sciences, Bristol Myers Squibb, Princeton, USA
| | - J Yao
- Informatics and Predictive Sciences, Bristol Myers Squibb, Princeton, USA
| | - J Neely
- Translational Medicine, Bristol Myers Squibb, Princeton, USA
| | - M Tschaika
- Oncology Clinical Development, Bristol Myers Squibb, Princeton, USA
| | - T H Welling
- Perlmutter Cancer Center and Department of Surgery, NYU Langone Health, New York, USA
| | - B Sangro
- Liver Unit and HPB Oncology Area, Clinica Universidad de Navarra and CIBEREHD, Pamplona, Spain
| |
Collapse
|
2
|
Yang Q, Yi SH, Fu BS, Zhang T, Zeng KN, Feng X, Yao J, Tang H, Li H, Zhang J, Zhang YC, Yi HM, Lyu HJ, Liu JR, Luo GJ, Ge M, Yao WF, Ren FF, Zhuo JF, Luo H, Zhu LP, Ren J, Lyu Y, Wang KX, Liu W, Chen GH, Yang Y. [Clinical application of split liver transplantation: a single center report of 203 cases]. Zhonghua Wai Ke Za Zhi 2024; 62:324-330. [PMID: 38432674 DOI: 10.3760/cma.j.cn112139-20231225-00297] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/05/2024]
Abstract
Objective: To investigate the safety and therapeutic effect of split liver transplantation (SLT) in clinical application. Methods: This is a retrospective case-series study. The clinical data of 203 consecutive SLT, 79 living donor liver transplantation (LDLT) and 1 298 whole liver transplantation (WLT) performed at the Third Affiliated Hospital of Sun Yat-sen University from July 2014 to July 2023 were retrospectively analyzed. Two hundred and three SLT liver grafts were obtained from 109 donors. One hundred and twenty-seven grafts were generated by in vitro splitting and 76 grafts were generated by in vivo splitting. There were 90 adult recipients and 113 pediatric recipients. According to time, SLT patients were divided into two groups: the early SLT group (40 cases, from July 2014 to December 2017) and the mature SLT technology group (163 cases, from January 2018 to July 2023). The survival of each group was analyzed and the main factors affecting the survival rate of SLT were analyzed. The Kaplan-Meier method and Log-rank test were used for survival analysis. Results: The cumulative survival rates at 1-, 3-, and 5-year were 74.58%, 71.47%, and 71.47% in the early SLT group, and 88.03%, 87.23%, and 87.23% in the mature SLT group, respectively. Survival rates in the mature SLT group were significantly higher than those in the early SLT group (χ2=5.560,P=0.018). The cumulative survival rates at 1-, 3- and 5-year were 93.41%, 93.41%, 89.95% in the LDLT group and 87.38%, 81.98%, 77.04% in the WLT group, respectively. There was no significant difference among the mature SLT group, the LDLT group and the WLT group (χ2=4.016, P=0.134). Abdominal hemorrhage, infection, primary liver graft nonfunction,and portal vein thrombosis were the main causes of early postoperative death. Conclusion: SLT can achieve results comparable to those of WLT and LDLT in mature technology liver transplant centers, but it needs to go through a certain time learning curve.
Collapse
Affiliation(s)
- Q Yang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - S H Yi
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - B S Fu
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - T Zhang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - K N Zeng
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - X Feng
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - J Yao
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - H Tang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - H Li
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - J Zhang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - Y C Zhang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - H M Yi
- Organ transplant Intensive Care Unit, the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630
| | - H J Lyu
- Organ transplant Intensive Care Unit, the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630
| | - J R Liu
- Organ transplant Intensive Care Unit, the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630
| | - G J Luo
- Anesthesia & Surgery Center, the Third Affiliated Hospital of Sun Yat-sen University ,Guangzhou 510630
| | - M Ge
- Anesthesia & Surgery Center, the Third Affiliated Hospital of Sun Yat-sen University ,Guangzhou 510630
| | - W F Yao
- Anesthesia & Surgery Center, the Third Affiliated Hospital of Sun Yat-sen University ,Guangzhou 510630
| | - F F Ren
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - J F Zhuo
- Organ transplant Intensive Care Unit, the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630
| | - H Luo
- Anesthesia & Surgery Center, the Third Affiliated Hospital of Sun Yat-sen University ,Guangzhou 510630
| | - L P Zhu
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - J Ren
- Ultrasound Department of the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630
| | - Y Lyu
- Ultrasound Department of the Third Affiliated Hospital of Sun Yat-sen University,Guangzhou 510630
| | - K X Wang
- Organ Donation Department of the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou 510630, China
| | - W Liu
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - G H Chen
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| | - Y Yang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University, Institute of Organ Transplantation, Sun Yat-sen University, Guangdong Organ Transplantation Research Center, Guangdong Transplantation Medical Engineering Laboratory, Guangdong Provincial Key Laboratory of Liver Diseases, Guangzhou 510630
| |
Collapse
|
3
|
Yao J, Roth H, Anderson D, Lu H, Rong H, Baird K. Comparison of Spontaneous Pushing and Directed Pushing During the Second Stage of Labor Among Chinese Women Without Epidural Analgesia: Protocol for a Noninferior Feasibility Study. JMIR Res Protoc 2024; 13:e55701. [PMID: 38530330 PMCID: PMC11005428 DOI: 10.2196/55701] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/20/2023] [Revised: 02/18/2024] [Accepted: 02/26/2024] [Indexed: 03/27/2024] Open
Abstract
BACKGROUND Maternal pushing during the second stage of labor could influence labor progress and maternal-neonatal outcomes. Although the image of health care providers directing the laboring women to push during the second stage of labor could be commonly observed globally, this practice is not sufficiently researched and is questioned regarding its effectiveness and outcomes on the mother and baby. Meanwhile, a strategy referred to as "spontaneous pushing," which supports women to push by following their bodily urges, has been evaluated in several trials. However, in China, spontaneous pushing is not common practice. Notwithstanding the evaluation of spontaneous pushing, there is a lack of high-quality evidence to support either strategies of directed pushing or spontaneous pushing. OBJECTIVE This study aims to test the feasibility of a future randomized controlled trial to compare the effects of spontaneous pushing and directed pushing during the second stage of labor for maternal and neonatal outcomes in China. METHODS A nonrandomized, single-group, noninferiority feasibility study will be conducted in a public hospital in Hebei Province, China. In total, 105 women meeting the selection criteria will be recruited to receive the intervention (spontaneous pushing), while 105 sets of medical notes from women who received routine care (directed pushing) will be identified and reviewed to compare outcomes for both cohorts. A mixed methods approach will be used to assess primary outcomes (feasibility and acceptability) and secondary outcomes (effectiveness). RESULTS Data collection took place between May and October 2023. A total of 110 women were invited to participate in the intervention of spontaneous pushing. Midwives' interviews were conducted and will be transcribed for analysis in March 2024. The data analysis is planned to be completed by May 2024. CONCLUSIONS This feasibility study will provide important information by conducting a full-scale clinical trial in the future as well as the potential facilitators and barriers of it. A future randomized controlled trial is likely to have considerable policy and funding impacts regarding pushing management during the second stage of labor and improvement in women's childbirth experience. TRIAL REGISTRATION Chinese Clinical Trial Register ChiCTR2300071178; https://tinyurl.com/mudtnbft. INTERNATIONAL REGISTERED REPORT IDENTIFIER (IRRID) DERR1-10.2196/55701.
Collapse
Affiliation(s)
- Jiasi Yao
- School of Nursing, Hebei Medical University, Shijiazhuang, China
- Faculty of Health, University of Technology Sydney, Sydney, Australia
| | - Heike Roth
- School of Nursing and Midwifery, Faculty of Health, University of Technology Sydney, Sydney, Australia
- Collective for Midwifery, Child and Family Health, School of Nursing and Midwifery, Faculty of Health, University of Technology Sydney, Sydney, Australia
| | - Debra Anderson
- Faculty of Health, University of Technology Sydney, Sydney, Australia
| | - Hong Lu
- School of Nursing, Peking University, Beijing, China
| | - Huijuan Rong
- Department of Nursing, The Fourth Hospital of Shijiazhuang, Shijiazhuang, China
| | - Kathleen Baird
- School of Nursing and Midwifery, Faculty of Health, University of Technology Sydney, Sydney, Australia
- Collective for Midwifery, Child and Family Health, School of Nursing and Midwifery, Faculty of Health, University of Technology Sydney, Sydney, Australia
| |
Collapse
|
4
|
Tang ZL, Yao J, Zhang P, He X, Jia LL, Shi KL, Xia ZK, Gao CL. [A case of X-linked Alport syndrome with esophageal leiomyomatosis]. Zhonghua Er Ke Za Zhi 2024; 62:275-277. [PMID: 38378292 DOI: 10.3760/cma.j.cn112140-20231014-00287] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/22/2024]
Affiliation(s)
- Z L Tang
- Department of Pediatrics, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing 210002, China
| | - J Yao
- Department of Pediatrics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
| | - P Zhang
- Department of Pediatrics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
| | - X He
- Department of Pediatrics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
| | - L L Jia
- Department of Pediatrics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
| | - K L Shi
- Department of Pediatrics, Jinling School of Clinical Medicine, Nanjing Medical University, Nanjing 210002, China
| | - Z K Xia
- Department of Pediatrics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
| | - C L Gao
- Department of Pediatrics, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing 210002, China
| |
Collapse
|
5
|
Sun H, Wang AL, Yao J, Zheng JR, Qin QH, Sha WL, Wang XY, Gao Y, Li Z, Huang DX, Wang Q. [Incidence and related factors of antiviral drug resistance in HIV-infected pregnant and postpartum women in some areas of three western provinces of China from 2017 to 2019]. Zhonghua Yu Fang Yi Xue Za Zhi 2023; 57:1788-1793. [PMID: 38008567 DOI: 10.3760/cma.j.cn112150-20230213-00102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Subscribe] [Scholar Register] [Indexed: 11/28/2023]
Abstract
Objective: To analyze the incidence and related factors of drug resistance in HIV-infected pregnant and postpartum women in some areas of three western provinces of China from 2017 to 2019. Methods: From April 2017 to April 2019, face-to-face questionnaires and blood sample testing were conducted in all health care institutions providing maternal and perinatal care and midwifery-assisted services in 7 prevention of mother-to-child transmissi project areas in Xinjiang, Yunnan and Guangxi provinces/autonomous regions. Information was collected during the perinatal period and viral load, CD4+T lymphocytes and drug resistance genes were detected at the same time. The multivariate logistic regression model was used to analyze the relationship between different factors and drug resistance in HIV-infected pregnant and postpartum women. Results: A total of 655 HIV-infected pregnant and postpartum women were included in this study. The incidence of drug resistance was 3.4% (22/655), all of whom were cross-drug resistant. The rate of low, moderate and high drug resistance was 2.1% (14/655), 1.2% (8/655) and 0.8% (5/655), respectively. The drug resistance rate in the people who had previously used antiviral drugs was 1.9% (8/418), and the drug resistance rate in the people who had not used drugs was 5.9% (14/237). The NNRTI drug resistance accounted for 2.8% (18/655) and the NRTI drug resistance rate was 2.5% (16/655). The multivariate logistic regression model showed that the risk of HIV resistance was lower in pregnant women who had previously used antiviral drugs (OR=0.32, 95%CI: 0.11-0.76). Conclusion: Strengthening the management of antiviral drug use and focusing on pregnant and postpartum women who have not previously used antiviral drugs can help reduce the occurrence of drug-resistant mutations. Personalized antiviral therapy should be considered to achieve viral inhibition effects in clinical practice.
Collapse
Affiliation(s)
- H Sun
- National Center for Women and Children's Health, Chinese Centers for Disease Control and Prevention, Beijing 100081, China
| | - A L Wang
- National Center for Women and Children's Health, Chinese Centers for Disease Control and Prevention, Beijing 100081, China
| | - J Yao
- National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - J R Zheng
- Yunnan Provincial Maternal and Child Health Care Hospital, Kunming 650051, China
| | - Q H Qin
- Guangxi Zhuang Autonomous Region Maternal and Child Health Hospital, Nanning 530000, China
| | - W L Sha
- Xinjiang Maternal and Child Health Care Hospital, Urumqi 830000, China
| | - X Y Wang
- National Center for Women and Children's Health, Chinese Centers for Disease Control and Prevention, Beijing 100081, China
| | - Y Gao
- National Center for Women and Children's Health, Chinese Centers for Disease Control and Prevention, Beijing 100081, China
| | - Z Li
- National Center for Women and Children's Health, Chinese Centers for Disease Control and Prevention, Beijing 100081, China
| | - D X Huang
- National Center for Women and Children's Health, Chinese Centers for Disease Control and Prevention, Beijing 100081, China
| | - Q Wang
- National Center for Women and Children's Health, Chinese Centers for Disease Control and Prevention, Beijing 100081, China
| |
Collapse
|
6
|
Furuhama A, Kitazawa A, Yao J, Matos Dos Santos CE, Rathman J, Yang C, Ribeiro JV, Cross K, Myatt G, Raitano G, Benfenati E, Jeliazkova N, Saiakhov R, Chakravarti S, Foster RS, Bossa C, Battistelli CL, Benigni R, Sawada T, Wasada H, Hashimoto T, Wu M, Barzilay R, Daga PR, Clark RD, Mestres J, Montero A, Gregori-Puigjané E, Petkov P, Ivanova H, Mekenyan O, Matthews S, Guan D, Spicer J, Lui R, Uesawa Y, Kurosaki K, Matsuzaka Y, Sasaki S, Cronin MTD, Belfield SJ, Firman JW, Spînu N, Qiu M, Keca JM, Gini G, Li T, Tong W, Hong H, Liu Z, Igarashi Y, Yamada H, Sugiyama KI, Honma M. Evaluation of QSAR models for predicting mutagenicity: outcome of the Second Ames/QSAR international challenge project. SAR QSAR Environ Res 2023; 34:983-1001. [PMID: 38047445 DOI: 10.1080/1062936x.2023.2284902] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/11/2023] [Accepted: 11/13/2023] [Indexed: 12/05/2023]
Abstract
Quantitative structure-activity relationship (QSAR) models are powerful in silico tools for predicting the mutagenicity of unstable compounds, impurities and metabolites that are difficult to examine using the Ames test. Ideally, Ames/QSAR models for regulatory use should demonstrate high sensitivity, low false-negative rate and wide coverage of chemical space. To promote superior model development, the Division of Genetics and Mutagenesis, National Institute of Health Sciences, Japan (DGM/NIHS), conducted the Second Ames/QSAR International Challenge Project (2020-2022) as a successor to the First Project (2014-2017), with 21 teams from 11 countries participating. The DGM/NIHS provided a curated training dataset of approximately 12,000 chemicals and a trial dataset of approximately 1,600 chemicals, and each participating team predicted the Ames mutagenicity of each trial chemical using various Ames/QSAR models. The DGM/NIHS then provided the Ames test results for trial chemicals to assist in model improvement. Although overall model performance on the Second Project was not superior to that on the First, models from the eight teams participating in both projects achieved higher sensitivity than models from teams participating in only the Second Project. Thus, these evaluations have facilitated the development of QSAR models.
Collapse
Affiliation(s)
- A Furuhama
- Division of Genetics and Mutagenesis (DGM), National Institute of Health Sciences (NIHS), Kawasaki, Japan
| | - A Kitazawa
- Division of Genetics and Mutagenesis (DGM), National Institute of Health Sciences (NIHS), Kawasaki, Japan
| | - J Yao
- Key Laboratory of Fluorine and Nitrogen Chemistry and Advanced Materials (Chinese Academy of Sciences), Shanghai Institute of Organic Chemistry, Chinese Academy of Sciences (SIOC, CAS), Shanghai, China
| | - C E Matos Dos Santos
- Department of Computational Toxicology and In Silico Innovations, Altox Ltd, São Paulo-SP, Brazil
| | - J Rathman
- MN-AM, Nuremberg, Germany/Columbus, OH, USA
| | - C Yang
- MN-AM, Nuremberg, Germany/Columbus, OH, USA
| | | | - K Cross
- In Silico Department, Instem, Conshohocken, PA, USA
| | - G Myatt
- In Silico Department, Instem, Conshohocken, PA, USA
| | - G Raitano
- Laboratory of Environmental Toxicology and Chemistry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS (IRFMN), Milano, Italy
| | - E Benfenati
- Laboratory of Environmental Toxicology and Chemistry, Department of Environmental Health Sciences, Istituto di Ricerche Farmacologiche Mario Negri IRCCS (IRFMN), Milano, Italy
| | | | | | | | | | - C Bossa
- Environment and Health Department, Istituto Superiore di Sanità (ISS), Rome, Italy
| | - C Laura Battistelli
- Environment and Health Department, Istituto Superiore di Sanità (ISS), Rome, Italy
| | - R Benigni
- Environment and Health Department, Istituto Superiore di Sanità (ISS), Rome, Italy
- Alpha-PreTox, Rome, Italy
| | - T Sawada
- Faculty of Regional Studies, Gifu University, Gifu, Japan
- xenoBiotic Inc, Gifu, Japan
| | - H Wasada
- Faculty of Regional Studies, Gifu University, Gifu, Japan
| | - T Hashimoto
- Faculty of Regional Studies, Gifu University, Gifu, Japan
| | - M Wu
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | - R Barzilay
- Massachusetts Institute of Technology, Cambridge, MA, USA
| | - P R Daga
- Simulations Plus, Lancaster, CA, USA
| | - R D Clark
- Simulations Plus, Lancaster, CA, USA
| | | | | | | | - P Petkov
- LMC - Bourgas University, Bourgas, Bulgaria
| | - H Ivanova
- LMC - Bourgas University, Bourgas, Bulgaria
| | - O Mekenyan
- LMC - Bourgas University, Bourgas, Bulgaria
| | - S Matthews
- Computational Pharmacology & Toxicology Laboratory, Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - D Guan
- Computational Pharmacology & Toxicology Laboratory, Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - J Spicer
- Computational Pharmacology & Toxicology Laboratory, Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - R Lui
- Computational Pharmacology & Toxicology Laboratory, Discipline of Pharmacology, School of Pharmacy, Faculty of Medicine and Health, The University of Sydney, Sydney, Australia
| | - Y Uesawa
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan
| | - K Kurosaki
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan
| | - Y Matsuzaka
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan
| | - S Sasaki
- Department of Medical Molecular Informatics, Meiji Pharmaceutical University, Tokyo, Japan
| | - M T D Cronin
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK
| | - S J Belfield
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK
| | - J W Firman
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK
| | - N Spînu
- School of Pharmacy and Biomolecular Sciences, Liverpool John Moores University, Liverpool, UK
| | - M Qiu
- Evergreen AI, Inc, Toronto, Canada
| | - J M Keca
- Evergreen AI, Inc, Toronto, Canada
| | - G Gini
- Department of Electronics, Information and Bioengineering (DEIB), Politecnico di Milano, Milano, Italy
| | - T Li
- Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration (NCTR/FDA), Jefferson, AR, USA
| | - W Tong
- Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration (NCTR/FDA), Jefferson, AR, USA
| | - H Hong
- Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration (NCTR/FDA), Jefferson, AR, USA
| | - Z Liu
- Division of Bioinformatics and Biostatistics, National Center for Toxicological Research, U.S. Food and Drug Administration (NCTR/FDA), Jefferson, AR, USA
- Integrative Toxicology, Nonclinical Drug Safety, Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, USA
| | - Y Igarashi
- Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - H Yamada
- Artificial Intelligence Center for Health and Biomedical Research, National Institutes of Biomedical Innovation, Health and Nutrition (NIBIOHN), Osaka, Japan
| | - K-I Sugiyama
- Division of Genetics and Mutagenesis (DGM), National Institute of Health Sciences (NIHS), Kawasaki, Japan
| | - M Honma
- Division of Genetics and Mutagenesis (DGM), National Institute of Health Sciences (NIHS), Kawasaki, Japan
| |
Collapse
|
7
|
Niu X, Wang R, Zeng L, Liu F, Gu Y, Yao J, Wang L, Xun T. A photo-controlled, all-solid, and frequency-tunable ultra-wideband pulse generator. Rev Sci Instrum 2023; 94:103101. [PMID: 37787625 DOI: 10.1063/5.0153498] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Accepted: 09/12/2023] [Indexed: 10/04/2023]
Abstract
With the continuous exploration of the bioelectric effect, nanosecond and picosecond pulsed electric fields used in cancer therapy and drug introduction have attracted great attention. In this paper, an ultrashort pulsed electric field generator is proposed, which connects two photoconductive semiconductor switches in parallel to generate unipolar and bipolar pulses. We described the experimental scheme of the generator and the simulation of the radio frequency combiner. A 532 nm laser with pulse widths of 1 ns and 500 ps is used to trigger the photoconductive semiconductor switches. The experimental results show that the scheme can achieve adjustments of 357 and 720 MHz for the center frequency and the 3 dB bandwidth, respectively. The results confirm that this proposed scheme can be used for unipolar/bipolar frequency-adjustable ultra-wideband pulse generation.
Collapse
Affiliation(s)
- X Niu
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
| | - R Wang
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
| | - L Zeng
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
| | - F Liu
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
| | - Y Gu
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
| | - J Yao
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
- Nanhu Laser Laboratory, National University of Defense Technology, Changsha 410073, China
| | - L Wang
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
- Nanhu Laser Laboratory, National University of Defense Technology, Changsha 410073, China
| | - T Xun
- The College of Advanced Interdisciplinary Studies, National University of Defense Technology, Changsha 410073, China
- Nanhu Laser Laboratory, National University of Defense Technology, Changsha 410073, China
| |
Collapse
|
8
|
Lan W, Yao J, Cao M, Wang Z, Xiang B, Zhou J, Liao W, Liu X, Yang M, Zhang S, Zhao Y. Bifunctional Role of Monocyte Subsets in Modulating Radiotherapy Combined Intra-Tumor αCD40 Agonist Induced Abscopal Effect. Int J Radiat Oncol Biol Phys 2023; 117:S121. [PMID: 37784314 DOI: 10.1016/j.ijrobp.2023.06.459] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) Abscopal effect induced by radiotherapy and immune checkpoint blockade is a promising yet far from satisfactory strategy in clinical. The underlying immune mechanism, especially driven by monocytes remains poorly undefined. Monocytes consist of two phenotypically and functionally distinct subsets distinguished by expression of chemokine receptors CCR2 and CX3CR1: classical inflammatory Ly6ChiCCR2hi monocytes and nonclassical patrolling Ly6CloCCR2loCX3CR1hi monocytes. Monocytes differentiate and transit to other myeloid cells such as dendritic cells and macrophages according to various environmental cues. Herein we investigated the roles of monocyte subsets in modulating tumor control consisting of combination RT and myeloid checkpoint agonist αCD40 to specifically ignite myeloid cell activation. MATERIALS/METHODS To establish abscopal model, contralateral tumors were implanted in each mouse, while only one side were treated with RT (8 Gy × 3) + αCD40 agonist (50 μg, intra-tumor). Tumor volume and mice survival were compared in each group (control, RT, αCD40 and RT + αCD40). Ccr2RFP/+ Cx3cr1GFP/+ (R2 × 3), Ccr2RFP/RFPCx3cr1+/+ (R2-KO) and Ccr2+/+Cx3cr1GFP/GFP (X3-KO) mice were used for cell tracking and to dissect chemokine receptor CCR2 and CX3CR1 on monocyte. Tumor infiltrating immune cells were analyzed by flowcytometry and RNA-seq. RESULTS RT combined with αCD40 significantly dampened tumor growth on both ipsilateral and contralateral sides in abscopal model (p< 0.01), accompanied by upregulation of chemokine receptors CCR2 and CX3CR1 on myeloid cells were both increased in tumor and peripheral blood. Chemokine ligands CCL2, CCL3, CCL5, CCL7, CCL12 and CX3CL1 were upregulated in tumor after RT and αCD40 treatment, recruiting CCR2 and CX3CR1 expressing monocytes in situ. To elucidate the roles of CCR2 and CX3CR1 in mediating local and systemic anti-tumor immunity, R2 × 3, R2-KO and X3-KO mice with combined treatment were used. Tumor size on ipsilateral leg were similar among groups. However, tumor growth was significantly delayed on contralateral side in X3-KO mice while accelerated in R2-KO mice compared with that in R2 × 3 mice. Mechanistically, remarkable decrease of antigen presenting dendritic cells (MHCII+Ly6ChiCD11c+) were observed in R2-KO mice. Moreover, phagocytosis was strengthened in macrophages (F4/80+CD11b+) of X3-KO mice. CONCLUSION CX3CR1 deletion ignite anti-tumor immunity elicited by RT and αCD40 through enhanced phagocytosis in macrophages, while CCR2 deletion renders inferior tumor control through reduction of dendritic cells. Preferential targeting nonclassical patrolling monocyte may lead to enhanced local and systemic tumor control.
Collapse
Affiliation(s)
- W Lan
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - J Yao
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - M Cao
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China; Chengdu University of Traditional Chinese Medicine, Chengdu, China
| | - Z Wang
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - B Xiang
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - J Zhou
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - W Liao
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - X Liu
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - M Yang
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - S Zhang
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| | - Y Zhao
- Sichuan Cancer Hospital & Institute, Sichuan Cancer Center; Cancer Hospital affiliate to University of Electronic Science and Technology of China, Chengdu, China
| |
Collapse
|
9
|
Yao J, Liu XM, Yuan F, Luo TY, Lu ZN, Yan YF, Chang SS, Song GY. [Safety and efficacy of transcatheter aortic valve replacement using the "All in One" single artery/vessel technique]. Zhonghua Xin Xue Guan Bing Za Zhi 2023; 51:990-994. [PMID: 37709717 DOI: 10.3760/cma.j.cn112148-20230807-00058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/16/2023]
Abstract
Objective: To explore the safety and efficacy of transcatheter aortic valve replacement (TAVR) using the "All in One" single-artery/vessel technique. Methods: This is a retrospective study. A total of 30 consecutive patients underwent TAVR using the single artery/vascular technique in Beijing Anzhen Hospital from August to December 2021 were included. Baseline clinical data, operative situation, postoperative outcomes, and incidence of adverse events during hospitalization and at one month post TAVR were analyzed. Results: Mean age was (72.6±9.7) years, 16 were male patients, STS score was (4.73±3.12)%. Four patients were diagnosed as isolated aortic regurgitation (all with tricuspid aortic valves), and 26 patients were diagnosed as aortic stenosis (AS), 10 of whom with tricuspid aortic valves and 16 of whom with bicuspid aortic valves. The single-vessel technique was applied in 3 aortic stenosis cases; the single-artery technique was applied in 27 cases. Echocardiography was performed immediately after procedure and results showed no or trace perivalvular leak in 27 cases and small perivalvular leak in 3 cases; the mean aortic transvalvular gradient of 26 AS patients decreased from (50.4±16.0) mmHg (1 mmHg=0.133 kPa) to (9.4±3.2) mmHg (P<0.001). The procedure time was (64.8±18.9) min. There were no intraoperative death, valve displacement, conversion to surgery, coronary artery occlusion in all 30 patients. There were no major cardiac adverse events such as myocardial infarction or stroke occurred during hospitalization or at follow-up. One-month follow-up echocardiography indicated prosthesis works well. The symptoms were significantly alleviated, and the Kansas City Cardiomyopathy Score (KCCQ score) of all patients increased from 48.1±18.4 to 73.5±17.6 (P<0.001). Conclusions: TAVR using the single artery/vessel technique is safe and feasible. This technique is related to reduced access complications and worthy of wide application.
Collapse
Affiliation(s)
- J Yao
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| | - X M Liu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| | - F Yuan
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| | - T Y Luo
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| | - Z N Lu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| | - Y F Yan
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| | - S S Chang
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| | - G Y Song
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Beijing Institute of Heart, Lung, and Blood Vessel Diseases, Capital Medical University, Beijing 100029, China
| |
Collapse
|
10
|
Lin YY, Liu LF, Qiu HT, Hui ML, Yao J, Zhang TZ. [Mc Cune-Albright syndrome with multiple hemangiomas of maxillofacial bone: a case report]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2023; 58:712-714. [PMID: 37455118 DOI: 10.3760/cma.j.cn115330-20220906-00545] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Grants] [Subscribe] [Scholar Register] [Indexed: 07/18/2023]
Affiliation(s)
- Y Y Lin
- Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
| | - L F Liu
- Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
| | - H T Qiu
- Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
| | - M L Hui
- Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
| | - J Yao
- Department of Otorhinolaryngology, Head and Neck Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
| | - T Z Zhang
- Department of Oral and Maxillofacial Surgery, Affiliated Hospital of Guangdong Medical University, Zhanjiang 524000, China
| |
Collapse
|
11
|
Chang SS, Liu XM, Lu ZN, Yao J, Yin CQ, Wu WH, Yuan F, Luo TY, Jiang ZM, Song GY. [Feasibility study of using bridging temporary permanent pacemaker in patients with high-degree atrioventricular block after TAVR]. Zhonghua Xin Xue Guan Bing Za Zhi 2023; 51:648-655. [PMID: 37312484 DOI: 10.3760/cma.j.cn112148-20221116-00898] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
Objective: To determine the feasibility of using temporary permanent pacemaker (TPPM) in patients with high-degree atrioventricular block (AVB) after transcatheter aortic valve replacement (TAVR) as bridging strategy to reduce avoidable permanent pacemaker implantation. Methods: This is a prospective observational study. Consecutive patients undergoing TAVR at Beijing Anzhen Hospital and the First Affiliated Hospital of Zhengzhou University from August 2021 to February 2022 were screened. Patients with high-degree AVB and TPPM were included. Patients were followed up for 4 weeks with pacemaker interrogation at every week. The endpoint was the success rate of TPPM removal and free from permanent pacemaker at 1 month after TPPM. The criteria of removing TPPM was no indication of permanent pacing and no pacing signal in 12 lead electrocardiogram (EGG) and 24 hours dynamic EGG, meanwhile the last pacemaker interrogation indicated that ventricular pacing rate was 0. Routinely follow-up ECG was extended to 6 months after removal of TPPM. Results: Ten patients met the inclusion criteria for TPPM, aged (77.0±11.1) years, wirh 7 females. There were 7 patients with third-degree AVB, 1 patient with second-degree AVB, 2 patients with first degree AVB with PR interval>240 ms and LBBB with QRS duration>150 ms. TPPM were applied on the 10 patients for (35±7) days. Among 8 patients with high-degree AVB, 3 recovered to sinus rhythm, and 3 recovered to sinus rhythm with bundle branch block. The other 2 patients with persistent third-degree AVB received permanent pacemaker implantation. For the 2 patients with first-degree AVB and LBBB, PR interval shortened to within 200 ms. TPPM was successfully removed in 8 patients (8/10) at 1 month without permanent pacemaker implantation, of which 2 patients recovered within 24 hours after TAVR and 6 patients recovered 24 hours later after TAVR. No aggravation of conduction block or permanent pacemaker indication were observed in 8 patients during follow-up at 6 months. No procedure-related adverse events occurred in all patients. Conclusion: TPPM is reliable and safe to provide certain buffer time to distinguish whether a permanent pacemaker is necessary in patients with high-degree conduction block after TAVR.
Collapse
Affiliation(s)
- S S Chang
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - X M Liu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - Z N Lu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - J Yao
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - C Q Yin
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - W H Wu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - F Yuan
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - T Y Luo
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| | - Z M Jiang
- Department of Cardiology, First Affiliated Hospital of Zhengzhou University, Zhengzhou 450000, China
| | - G Y Song
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Centre for Cardiovascular Diseases, Beijing 100029, China
| |
Collapse
|
12
|
Peng P, Ji YQ, Zhao NH, Liu T, Wang H, Yao J. [Evaluation of peripheral blood T-lymphocyte subpopulations features in patients with hepatitis B virus-related acute-on-chronic liver failure based on single-cell sequencing technology]. Zhonghua Gan Zang Bing Za Zhi 2023; 31:422-427. [PMID: 37248982 DOI: 10.3760/cma.j.cn501113-20220205-00056] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 05/31/2023]
Abstract
Objective: T lymphocyte exhaustion is an important component of immune dysfunction. Therefore, exploring peripheral blood-exhausted T lymphocyte features in patients with hepatitis B virus-related acute-on-chronic liver failure may provide potential therapeutic target molecules for ACLF immune dysfunction. Methods: Six cases with HBV-ACLF and three healthy controls were selected for T-cell heterogeneity detection using the single-cell RNA sequencing method. In addition, exhausted T lymphocyte subpopulations were screened to analyze their gene expression features, and their developmental trajectories quasi-timing. An independent sample t-test was used to compare the samples between the two groups. Results: Peripheral blood T lymphocytes in HBV-ACLF patients had different differentiation trajectories with different features distinct into eight subpopulations. Among them, the CD4(+)TIGIT(+) subsets (P = 0.007) and CD8(+)LAG3(+) (P = 0.010) subsets with highly exhausted genes were significantly higher than those in healthy controls. Quasi-time analysis showed that CD4(+)TIGIT(+) and CD8(+)LAG3(+) subsets appeared in the late stage of T lymphocyte differentiation, suggesting the transition of T lymphocyte from naïve-effector-exhausted during ACLF pathogenesis. Conclusion: There is heterogeneity in peripheral blood T lymphocyte differentiation in patients with HBV-ACLF, and the number of exhausted T cells featured by CD4(+)TIGIT(+)T cell and CD8(+)LAG3(+) T cell subsets increases significantly, suggesting that T lymphocyte immune exhaustion is involved in the immune dysfunction of HBV-ACLF, thereby identifying potential effective target molecules for improving ACLF patients' immune function.
Collapse
Affiliation(s)
- P Peng
- Department of Gastroenterology, Shanxi Provincial People's Hospital, Taiyuan 030031, China
| | - Y Q Ji
- Department of Biochemistry and Molecular Biology, Basic Medical College, Shanxi Medical University, Taiyuan 030000, China
| | - N H Zhao
- Department of Gastroenterology, Shanxi Bethune Hospital, Taiyuan 030032, China
| | - T Liu
- Department of Gastroenterology, Shanxi Bethune Hospital, Taiyuan 030032, China
| | - H Wang
- Department of Gastroenterology, Shanxi Bethune Hospital, Taiyuan 030032, China
| | - J Yao
- Department of Gastroenterology, Shanxi Bethune Hospital, Taiyuan 030032, China
| |
Collapse
|
13
|
Liu XM, Yao J, Dong Z, Yin CQ, Wu WH, Yuan F, Luo TY, Chang SS, Yan YF, Pu JZ, Song GY. [Transcatheter aortic valve replacement via single-vessel approach technique:a case report]. Zhonghua Xin Xue Guan Bing Za Zhi 2023; 51:73-75. [PMID: 36655245 DOI: 10.3760/cma.j.cn112148-20221130-00947] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 01/20/2023]
Affiliation(s)
- X M Liu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - J Yao
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - Z Dong
- Integrated Traditional and Western Medicine Department of Cardiology, China-Japan Friendship Hospital, Beijing 100029, China
| | - C Q Yin
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - W H Wu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - F Yuan
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - T Y Luo
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - S S Chang
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - Y F Yan
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - J Z Pu
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| | - G Y Song
- Interventional Center of Valvular Heart Disease, Beijing Anzhen Hospital, Capital Medical University, National Clinical Research Center of Cardiovascular Diseases, Beijing 100029, China
| |
Collapse
|
14
|
Current J, Chaney H, Chimino G, Dugan E, Yao J. 214. Reprod Fertil Dev 2022. [DOI: 10.1071/rdv35n2ab214] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
15
|
Chaney H, Current J, Yao J. 109 Agouti-signalling protein impacts blastocyst development in cattle. Reprod Fertil Dev 2022. [DOI: 10.1071/rdv35n2ab109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022] Open
|
16
|
Wu YL, Zhou Q, Pan Y, Yang X, Zhao Y, Han G, Pang Q, Zhang Z, Wang Q, Yao J, Wang H, Yang W, Liu B, Chen Q, Du X, Cai K, Li B, Shuang J, Song L, Shi W. LBA5 A phase II study of neoadjuvant SHR-1701 with or without chemotherapy (chemo) followed by surgery or radiotherapy (RT) in stage III unresectable NSCLC (uNSCLC). Immuno-Oncology and Technology 2022. [DOI: 10.1016/j.iotech.2022.100361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/13/2022]
|
17
|
Guo LD, Zhao XH, Liu YY, Zuo XR, Yao J, Sun JR, Xu DM, Li FP, Li WH. In Situ Ligand Synthesis Afforded Two New Metal-Organic Compounds: Luminescent and Photocatalytic Properties. RUSS J INORG CHEM+ 2022. [DOI: 10.1134/s0036023622700097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022]
|
18
|
Lu D, Yao J, Yuan G, Gao Y, Zhang J, Guo X. Immune checkpoint inhibitor-associated new-onset primary adrenal insufficiency: a retrospective analysis using the FAERS. J Endocrinol Invest 2022; 45:2131-2137. [PMID: 35870109 PMCID: PMC9525402 DOI: 10.1007/s40618-022-01845-z] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/14/2021] [Accepted: 06/18/2022] [Indexed: 12/20/2022]
Abstract
BACKGROUND Our study aimed to investigate the prevalence and demographic characteristics of immune checkpoint inhibitor-associated primary adrenal insufficiency (ICI-PAI) and to explore the risk factors of its clinical outcome using data from the US FDA Adverse Event Reporting System (FAERS). METHODS This was a retrospective study. All cases of new-onset or newly diagnosed primary adrenal insufficiency associated with FDA-approved ICIs from 1 January 2007 to 31 December 2020 were identified and collected using FAERS. Data on age, sex category, body weight of the participating individuals, the reporting year and the prognosis of cases, and other accompanying endocrinopathies related to ICIs, were analysed. RESULTS The incidence of ICI-PAI was 1.03% (1180/114121). Of the 1180 cases of PAI, 46 were "confirmed PAI", and 1134 were "suspected PAI". Combination therapy with anti-CTLA-4 and anti-PD-1 was related to a higher risk of PAI compared with the anti-PD-1-only group (χ2 = 92.88, p < 0.001). Male and elderly individuals showed a higher risk of ICI-PAI (male vs. female, 1.17% vs. 0.94%, χ2 = 12.55, p < 0.001; age < 65 vs. ≥ 65, 1.20 vs. 1.41%, χ2 = 6.89, p = 0.009). The co-occurrence rate of endocrinopathies other than PAI was 24.3%, which showed a higher trend in patients on nivolumab-ipilimumab treatment than in those on PD-1 inhibitors (χ2 = 3.227, p = 0.072). Body weight was negatively associated with the risk of death in the study population [p = 0.033 for the regression model; B = - 0.017, OR 0.984, 95% CI (0.969-0.998), p = 0.029]. CONCLUSION ICI-associated PAI is a rare but important irAE. Male and elderly patients have a higher risk of ICI-PAI. Awareness among clinicians is critical when patients with a lower body weight develop PAI, which indicates a higher risk of a poor clinical outcome.
Collapse
Affiliation(s)
- D. Lu
- Department of Endocrinology, Peking University First Hospital, Beijing, 100034 People’s Republic of China
| | - J. Yao
- Department of Endocrinology, Peking University First Hospital, Beijing, 100034 People’s Republic of China
| | - G. Yuan
- Department of Endocrinology, Peking University First Hospital, Beijing, 100034 People’s Republic of China
| | - Y. Gao
- Department of Endocrinology, Peking University First Hospital, Beijing, 100034 People’s Republic of China
| | - J. Zhang
- Department of Endocrinology, Peking University First Hospital, Beijing, 100034 People’s Republic of China
| | - X. Guo
- Department of Endocrinology, Peking University First Hospital, Beijing, 100034 People’s Republic of China
| |
Collapse
|
19
|
He Y, Pang Y, Su Z, Zhou Y, Wang Y, Lu Y, Jiang Y, Han X, Song L, Wang L, Li Z, Lv X, Wang Y, Yao J, Liu X, Zhou X, He S, Zhang Y, Song L, Li J, Wang B, Tang L. Symptom burden, psychological distress, and symptom management status in hospitalized patients with advanced cancer: a multicenter study in China. ESMO Open 2022; 7:100595. [PMID: 36252435 PMCID: PMC9808454 DOI: 10.1016/j.esmoop.2022.100595] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/20/2022] [Revised: 08/31/2022] [Accepted: 09/02/2022] [Indexed: 01/07/2023] Open
Abstract
BACKGROUND The management of physical symptoms and psychological distress of cancer patients is an important component of cancer care. The purpose of this study was to evaluate the symptom burden, psychological distress, and management status of hospitalized patients with advanced cancer in China and explore the potential influencing factors of undertreatment and non-treatment of symptoms. PATIENTS AND METHODS A total of 2930 hospitalized patients with advanced cancer (top six types of cancer in China) were recruited from 10 centers all over China. Patient-reported MD Anderson Symptom Inventory, Hospital Anxiety and Depression Scale (HADS), and Patient Health Questionnaire-9 (PHQ-9) scales and symptom management-related information were collected and linked with the patient's clinical data. The proportion of patients reporting moderate-to-severe (MS) symptoms and whether they were currently well managed were examined. Multivariable logistic regression models were applied to explore the factors correlated to undertreatment and non-treatment of symptoms. RESULTS About 27% of patients reported over three MS symptoms, 16% reported over five, and 9% reported over seven. Regarding psychological distress, the prevalence of HADS-anxiety was 29% and that of PHQ-9 depression was 11%. Sixty-one percent of patients have at least one MS symptom without any treatment. Sex [odds ratio (OR) = 2.238, 95% confidence interval (95% CI) 1.502-3.336], Eastern Cooperative Oncology Group (ECOG; OR = 0.404, 95% CI 0.241-0.676), and whether currently undergoing anticancer treatment (OR = 0.667, 95% CI 0.503-0.886) are the main factors correlated with the undertreatment of symptoms. Age (OR = 1.972, 95% CI 1.263-3.336), sex (OR = 0.626, 95% CI 0.414-0.948), ECOG (OR = 0.266, 95% CI 0.175-0.403), whether currently undergoing anticancer treatment (OR = 0.356, 95% CI 0.249-0.509), and comorbidity (OR = 0.713, 95% CI 0.526-0.966) are the main factors correlated with the non-treatment of symptoms. CONCLUSIONS This study shows that hospitalized patients with advanced cancer had a variety of physical and psychological symptoms but lacked adequate management and suggests that a complete symptom screening and management system is needed to deal with this complex problem.
Collapse
Affiliation(s)
- Y. He
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Y. Pang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Z. Su
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Y. Zhou
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Y. Wang
- Department of Breast Cancer Radiotherapy, Chinese Academy of Medical Sciences, Cancer Hospital Affiliated to Shanxi Medical University, Taiyuan, China
| | - Y. Lu
- The Fifth Department of Chemotherapy, The Affiliated Cancer Hospital of Guangxi Medical University, Guangxi Zhuang Autonomous Region, Nanning, China
| | - Y. Jiang
- Department of Medical Oncology, Cancer Center, West China Hospital, Sichuan University, Chengdu, China
| | - X. Han
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - L. Song
- Department of Breast Medical Oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - L. Wang
- Department of Oncology, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
| | - Z. Li
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - X. Lv
- Department of Oncology, Xiamen Humanity Hospital, Xiamen, China
| | - Y. Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - J. Yao
- Department of Integrated Chinese and Western Medicine, Shaanxi Provincial Cancer Hospital Affiliated to Medical College of Xi'an Jiaotong University, Xi'an, China
| | - X. Liu
- Department of Clinical Spiritual Care, Hunan Cancer Hospital/The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China
| | - X. Zhou
- Radiotherapy Center, Hubei Cancer Hospital, Wuhan, China
| | - S. He
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - Y. Zhang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - L. Song
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - J. Li
- Department of Psycho-oncology, Shandong Cancer Hospital and Institute, Shandong First Medical University and Shandong Academy of Medical Sciences, Jinan, China
| | - B. Wang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China
| | - L. Tang
- Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Psycho-oncology, Peking University Cancer Hospital & Institute, Beijing, China,Correspondence to: Dr Lili Tang, Fu-Cheng Road 52, Hai-Dian District, Beijing 100142, China. Tel: +86-1088196648
| |
Collapse
|
20
|
Fu BS, Yi SH, Yi HM, Feng X, Zhang T, Yang Q, Zhang YC, Yao J, Tang H, Zeng KN, Li XB, Yang Z, Lyu L, Chen GH, Yang Y. [Clinical efficacy of split liver transplantation in the treatment of children with biliary atresia]. Zhonghua Wai Ke Za Zhi 2022; 60:900-905. [PMID: 36207978 DOI: 10.3760/cma.j.cn112139-20220712-00309] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To compare the clinical efficacy of split liver transplantation (SLT) and living donor liver transplantation(LDLT) in the treatment of children with biliary atresia. Methods: The clinical data of 64 children with biliary atresia who underwent SLT and 44 children who underwent LDLT from June 2017 to May 2022 at Liver Surgery & Liver Transplantation Center,the Third Affiliated Hospital of Sun Yat-sen University were retrospectively analyzed. Among the children who received SLT, there were 40 males and 24 females. The median age at transplantation was 8 months (range:4 to 168 months). Among the patients who received LDLT, there were 24 males and 20 females. The age at transplantation ranged from 4 to 24 months,with a median age of 7 months. Sixty-four children with biliary atresia were divided into two groups according to the SLT operation time: 32 cases in the early SLT group(June 2017 to January 2019) and 32 cases in the technically mature SLT group (February 2019 to May 2022). Rank sum test or t test was used to compare the recovery of liver function between the LDLT group and the SLT group,and between the early SLT group and the technically mature SLT group. The incidence of postoperative complications was compared by χ2 test or Fisher exact probability method. Kaplan-Meier method and Log-rank test were used for survival analysis. Results: The cold ischemia time(M (IQR)) (218 (65) minutes), intraoperative blood loss(175 (100) ml) and graft-to-recipient body weight ratio (3.0±0.7) in the LDLT group were lower than those in the SLT group(500 (130) minutes, 200 (250) ml, 3.4±0.8) (Z=-8.064,Z=-2.969, t=-2.048, all P<0.05). The cold ischemia time(457(158)minutes) and total hospital stay ((37.4±22.4)days) in the technically mature SLT group were lower than those in the early SLT group(510(60)minutes, (53.0±39.0)days).The differences were statistically significant (Z=-2.132, t=1.934, both P<0.05).The liver function indexes of LDLT group and SLT group showed unimodal changes within 1 week after operation. The peak values of ALT, AST, prothrombin time, activeated partial thromboplasting time, international normalized ratio, fibrinogen and creatinine all appeared at 1 day after operation, and the peak value of prothrombin activity appeared at 3 days after operation. All indicators returned to normal at 7 days after operation. The 1-,2-,and 3-year overall survival rates were 95.5% in LDLT group and 93.5% in the technically mature SLT group, and the difference was not statistically significant. The 1-,2-,and 3-year overall survival rates were 90.2% in the early SLT group and 93.5% in the technically mature SLT group, and there was no significant difference between the two groups(P>0.05). The main complications of the early SLT group were surgery-related complications(28.1%,9/32), and the main complications of the technically mature SLT group were non-surgery-related complications(21.9%,7/32). There were 5 deaths in the SLT group,including 4 in the early SLT group and 1 in the technically mature SLT group. Conclusion: The survival rate of SLT in the treatment of biliary atresia is comparable to that of LDLT.
Collapse
Affiliation(s)
- B S Fu
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - S H Yi
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - H M Yi
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - X Feng
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - T Zhang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - Q Yang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - Y C Zhang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - J Yao
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - H Tang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - K N Zeng
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - X B Li
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - Z Yang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - L Lyu
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - G H Chen
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| | - Y Yang
- Liver Surgery & Liver Transplantation Center, the Third Affiliated Hospital of Sun Yat-sen University;Institute of Organ Transplantation,Sun Yat-sen University;Guangdong Organ Transplantation Research Center;Guangdong Transplantation Medical Engineering Laboratory;Guangdong Provincial Key Laboratory of Liver Diseases,Guangzhou 510630,China
| |
Collapse
|
21
|
Wang L, Qin S, Zhou Y, Zhang S, Sun X, Chen Z, Cui J, Zhao P, Gu K, Li Z, Wang J, Chen X, Yao J, Shen L, Zhou J, Wang G, Bai Y, Wang Q, Wang H. LBA61 HR070803 plus 5-FU/LV versus placebo plus 5-FU/LV in second-line therapy for gemcitabine-refractory locally advanced or metastatic pancreatic cancer: A multicentered, randomized, double-blind, parallel-controlled phase III trial (HR-IRI-APC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
22
|
Lin G, Wang A, Li F, Gu P, Zhou H, Yao J, Wang M, Liu W, Zheng X, Zheng X. EP16.02-016 Exploration of Factors Affecting the Performance of MRD Tumor-Informed Assay in Chinese Lung Cancer Patients. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1047] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
23
|
Shen L, Gong J, Li N, Guo W, Zhang J, Fan Q, Liu T, Xia Z, Y. Shen, Wang J, Lu L, Qi C, Yao J, Qian X, Shi M. 1254P Updated report of a phase I study of TST001, a humanized anti-CLDN18.2 monoclonal antibody, in combination with capecitabine and oxaliplatin (CAPOX) as a first-line treatment of advanced G/GEJ cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1372] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
24
|
Huang J, Ding Y, Yao J, Peng K, Deng K, Zhang M, Zhang Y, Zuo J. The SARS-CoV-2 rS1-E-PLGA nanovaccine and evaluation of its immune effect in BALB/c mice. Eur Rev Med Pharmacol Sci 2022; 26:5255-5263. [PMID: 35916825 DOI: 10.26355/eurrev_202207_29316] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/15/2023]
Abstract
OBJECTIVE Vaccination is an important method for preventing COVID-19 infection. However, certain vaccines do not meet the current needs. To improve the vaccine effect, discard ineffective antigens, and focus on high-quality antigenic clusters, S1-E bivalent antigens were designed. MATERIALS AND METHODS Vaccine delivery is performed using poly (lactic-co-glycolic acid) (PLGA). Here, the recombinant S1-E (rS1-E) was covered on PLGA and injected intramuscularly into mice. In total, 48 BALB/c mice were randomly divided into six groups with 8 mice in each group. The mice received intramuscular injections. Prior to vaccination, the hydrophobicity of the rS1-E and the antigenic site of the E protein were both analysed. The morphology, zeta potential, and particle size distribution of rS1-E-PLGA were examined. Anti-S1 and anti-E antibodies were detected in mouse serum by ELISA. Neutralising an-tibodies were detected by co-incubating the pseudovirus with the obtained serum. IL-2 and TNF-α levels were also measured. RESULTS The designed recombinant S1-E protein was successfully coated on PLGA nanoparticles. rS1-E-PLGA nanovaccine has suitable size, shape, good stability, sustained release and other characteristics. Importantly, mice were stimulated with rS1-E-PLGA nanovaccines to produce high-titre antibodies and a good cellular immune response. CONCLUSIONS Our results indicate that rS1-E-PLGA nanovaccine may provide a good protective effect, and the vaccine should be further investigated in human clinical trials for use in vaccination or as a booster.
Collapse
Affiliation(s)
- J Huang
- The Laboratory of Translational Medicine, Nanhua Hospital Affiliated to University of South China, The Third Affiliated Hospital of University of South China, Institute of Pathogenic Biology, Hengyang Medical School, University of South China, Hengyang, Hunan, P.R. China.
| | | | | | | | | | | | | | | |
Collapse
|
25
|
Luan X, Gao Z, Sun J, Chen G, Yan S, Yu H, Song H, Yao J, Song P. Feasibility of an ultra-low dose contrast media protocol for coronary CT angiography. Clin Radiol 2022; 77:e705-e710. [PMID: 35778294 DOI: 10.1016/j.crad.2022.05.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 05/30/2022] [Accepted: 05/30/2022] [Indexed: 11/25/2022]
Abstract
AIM To evaluate the feasibility of an ultra-low volume contrast media (CM) protocol for coronary computed tomography angiography (CTA). MATERIALS AND METHODS In total, 214 patients receiving coronary CTA were enrolled prospectively and divided into group A (n=107) receiving a conventional dose of CM and group B (n=107) receiving an ultra-low dose. CT values of the right coronary artery (RCA), left anterior descending artery (LAD), and left circumflex artery (LCX) were measured and radiation doses recorded. The image quality was compared between the groups. Changes in renal function indices and proteinuria before, 24, and 72 hours after coronary CTA among those with chronic kidney disease (CKD) were also assessed. RESULTS There were significant differences in CT values and radiation doses between groups A and B. In group A, the average RCA, LAD, and LCX CT values were 412.5 ± 79.2, 423.5 ± 73.7, and 422.0 ± 88.1 HU, respectively. In group B, the average RCA, LAD, and LCX CT values were 275.2 ± 16.2, 277.8 ± 16.4, and 278.9 ± 16.5 HU, respectively. The radiation dose in the ultra-low protocol recipients (118.70 ± 18.52 mGy·cm) was significantly lower than that used in conventional coronary CTA (131.75 ± 20.96 mGy·cm). The image quality of group B was comparable to that of group A, satisfying the diagnostic requirement. In patients with mild CKD, there were no significant differences in renal functions after coronary CTA. CONCLUSION An ultra-low CM protocol was established for coronary CTA, providing comparable image quality and diagnostic yields but significantly lower radiation dose compared with a conventional protocol. This new protocol might be applicable to patients with mild CKD.
Collapse
Affiliation(s)
- X Luan
- Weifang Medical University, Weifang 261053, China; Jinan Central Hospital, Jinan 250013, China
| | - Z Gao
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
| | - J Sun
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
| | - G Chen
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
| | - S Yan
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
| | - H Yu
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
| | - H Song
- The Institute for Tissue Engineering and Regenerative Medicine, The Liaocheng University/liaocheng People's Hospital, Liaocheng 252000, China
| | - J Yao
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
| | - P Song
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China.
| |
Collapse
|
26
|
Melero I, Yau T, Kang Y, Kim T, Santoro A, Sangro B, Kudo M, Hou M, Matilla A, Tovoli F, Knox J, He A, El-Rayes B, Acosta-Rivera M, Lim H, Soleymani S, Yao J, Neely J, Tschaika M, Hsu C, El-Khoueiry A. SO-12 Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients with advanced hepatocellular carcinoma (aHCC): 5-year results from CheckMate 040. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.04.411] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
27
|
Siland JE, Geelhoed B, Roselli C, Wang B, Lin HJ, Weiss S, Trompet S, van den Berg ME, Soliman EZ, Chen LY, Ford I, Jukema JW, Macfarlane PW, Kornej J, Lin H, Lunetta KL, Kavousi M, Kors JA, Ikram MA, Guo X, Yao J, Dörr M, Felix SB, Völker U, Sotoodehnia N, Arking DE, Stricker BH, Heckbert SR, Lubitz SA, Benjamin EJ, Alonso A, Ellinor PT, van der Harst P, Rienstra M. Resting heart rate and incident atrial fibrillation: A stratified Mendelian randomization in the AFGen consortium. PLoS One 2022; 17:e0268768. [PMID: 35594314 PMCID: PMC9122202 DOI: 10.1371/journal.pone.0268768] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 05/06/2022] [Indexed: 12/02/2022] Open
Abstract
Background Both elevated and low resting heart rates are associated with atrial fibrillation (AF), suggesting a U-shaped relationship. However, evidence for a U-shaped causal association between genetically-determined resting heart rate and incident AF is limited. We investigated potential directional changes of the causal association between genetically-determined resting heart rate and incident AF. Method and results Seven cohorts of the AFGen consortium contributed data to this meta-analysis. All participants were of European ancestry with known AF status, genotype information, and a heart rate measurement from a baseline electrocardiogram (ECG). Three strata of instrumental variable-free resting heart rate were used to assess possible non-linear associations between genetically-determined resting heart rate and the logarithm of the incident AF hazard rate: <65; 65–75; and >75 beats per minute (bpm). Mendelian randomization analyses using a weighted resting heart rate polygenic risk score were performed for each stratum. We studied 38,981 individuals (mean age 59±10 years, 54% women) with a mean resting heart rate of 67±11 bpm. During a mean follow-up of 13±5 years, 4,779 (12%) individuals developed AF. A U-shaped association between the resting heart rate and the incident AF-hazard ratio was observed. Genetically-determined resting heart rate was inversely associated with incident AF for instrumental variable-free resting heart rates below 65 bpm (hazard ratio for genetically-determined resting heart rate, 0.96; 95% confidence interval, 0.94–0.99; p = 0.01). Genetically-determined resting heart rate was not associated with incident AF in the other two strata. Conclusions For resting heart rates below 65 bpm, our results support an inverse causal association between genetically-determined resting heart rate and incident AF.
Collapse
Affiliation(s)
- J. E. Siland
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - B. Geelhoed
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
| | - C. Roselli
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, United States of America
| | - B. Wang
- Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America
| | - H. J. Lin
- Institute for Translational Genomics and Population Sciences, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, United States of America
- Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America
| | - S. Weiss
- Interfaculty Institute for Genetics and Functional Genomics; Department of Functional Genomics; University Medicine Greifswald, Greifswald, Germany
- DZHK (German Centre for Cardiovascular Research); partner site Greifswald, Greifswald, Germany
| | - S. Trompet
- Department of Cardiology, Leiden University Medical Center, Leiden, The Netherlands
- Department of Internal Medicine, Section of Gerontology and Geriatrics, Leiden University Medical Center, Leiden, The Netherlands
| | - M. E. van den Berg
- Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - E. Z. Soliman
- Division of Public Health Sciences and Department of Medicine, Epidemiological Cardiology Research Center, Department of Epidemiology and Prevention, Section on Cardiology, Wake Forest School of Medicine, Winston-Salem, NC, United States of America
| | - L. Y. Chen
- Cardiovascular Division, Department of Medicine, University of Minnesota Medical School, Minneapolis, MN, United States of America
| | - I. Ford
- Robertson Centre for Biostatistics, University of Glasgow, Glasgow, United Kingdom
| | - J. W. Jukema
- DZHK (German Centre for Cardiovascular Research); partner site Greifswald, Greifswald, Germany
- Einthoven Laboratory for Experimental Vascular Medicine, LUMC, Leiden, The Netherlands
- Netherlands Heart Institute, Utrecht, The Netherlands
| | - P. W. Macfarlane
- Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
| | - J. Kornej
- National Heart, Lung, and Blood Institute’s and Boston University’s Framingham Heart Study, Framingham, MA, United States of America
| | - H. Lin
- National Heart Lung and Blood Institute’s and Boston University’s Framingham Heart Study, Framingham, MA, United States of America
- Section of Computational Biomedicine, Department of Medicine, Boston University School of Medicine, Boston, MA, Unites States of America
| | - K. L. Lunetta
- Department of Biostatistics, Boston University School of Public Health, Boston, MA, United States of America
- National Heart, Lung, and Blood Institute’s and Boston University’s Framingham Heart Study, Framingham, MA, United States of America
| | - M. Kavousi
- Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - J. A. Kors
- Department of Medical Informatics, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - M. A. Ikram
- Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - X. Guo
- Institute for Translational Genomics and Population Sciences, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, United States of America
- Department of Pediatrics, David Geffen School of Medicine at UCLA, Los Angeles, CA, United States of America
| | - J. Yao
- Institute for Translational Genomics and Population Sciences, Department of Pediatrics, The Lundquist Institute at Harbor-UCLA Medical Center, Torrance, CA, United States of America
| | - M. Dörr
- DZHK (German Centre for Cardiovascular Research); partner site Greifswald, Greifswald, Germany
- Department of Internal Medicine B-Cardiology, Pneumology, Infectious Diseases, Intensive Care Medicine, University Medicine Greifswald, Greifswald, Germany
| | - S. B. Felix
- DZHK (German Centre for Cardiovascular Research); partner site Greifswald, Greifswald, Germany
- Department of Internal Medicine B-Cardiology, Pneumology, Infectious Diseases, Intensive Care Medicine, University Medicine Greifswald, Greifswald, Germany
| | - U. Völker
- Interfaculty Institute for Genetics and Functional Genomics; Department of Functional Genomics; University Medicine Greifswald, Greifswald, Germany
- DZHK (German Centre for Cardiovascular Research); partner site Greifswald, Greifswald, Germany
| | - N. Sotoodehnia
- Cardiovascular Health Research Unit, Division of Cardiology, Departments of Medicine and Epidemiology, University of Washington, Seattle, WA, Unites States of America
| | - D. E. Arking
- McKusick-Nathans Institute, Department of Genetic Medicine, Johns Hopkins University SOM, Baltimore, MD, Unites States of America
| | - B. H. Stricker
- Department of Epidemiology, Erasmus University Medical Center Rotterdam, Rotterdam, The Netherlands
| | - S. R. Heckbert
- Cardiovascular Health Research Unit and the Department of Epidemiology, University of Washington, Seattle, WA, Unites States of America
| | - S. A. Lubitz
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, United States of America
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, Unites States of America
- Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA, Unites States of America
| | - E. J. Benjamin
- Institute of Health and Wellbeing, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow, United Kingdom
- Department of Medicine, Boston University School of Medicine, Boston, MA, Unites States of America
- Department of Epidemiology, Boston University School of Public Health, Boston, MA, Unites States of America
| | - A. Alonso
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, GA, Unites States of America
| | - P. T. Ellinor
- Cardiovascular Disease Initiative, The Broad Institute of MIT and Harvard, Cambridge, MA, United States of America
- Cardiovascular Research Center, Massachusetts General Hospital, Boston, MA, Unites States of America
- Cardiac Arrhythmia Service, Massachusetts General Hospital, Boston, MA, Unites States of America
| | - P. van der Harst
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- University of Groningen, University Medical Center Groningen, Department of Genetics, Groningen, The Netherlands
- University Medical Center Utrecht, Department of Heart and Lungs, University of Utrecht, Utrecht, The Netherlands
| | - M. Rienstra
- Department of Cardiology, University of Groningen, University Medical Center Groningen, Groningen, The Netherlands
- * E-mail:
| |
Collapse
|
28
|
Zhang R, Dong TL, Liang WL, Cao ZB, Xie Z, Liu KM, Yu F, Fu GF, Zhang YQ, Wang GY, Ma QQ, Wu SB, Li Y, Dong W, Jiang Z, Xu J, Wu ZY, Yao J, Pan PL, Qiu MF. [Analysis of HIV-1 genetic subtype and pretreatment drug resistance among men who have sex with men infected with HIV-1 from 19 cities of 6 provinces in China]. Zhonghua Liu Xing Bing Xue Za Zhi 2022; 43:523-527. [PMID: 35443307 DOI: 10.3760/cma.j.cn112338-20211125-00918] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To investigate the distribution of HIV-1 genetic subtypes and pretreatment drug resistance (PDR) among men who have sex with men (MSM) from 19 cities of 6 provinces in China. Methods: From April to November 2019, 574 plasma samples of ART-naive HIV-1 infected MSM were collected from 19 cities in Hebei, Shandong, Jiangsu, Zhejiang, Fujian, and Guangdong provinces, total ribonucleic acid (RNA) was extracted and amplified the HIV-1 pol gene region by nested polymerase chain reaction (PCR) after reverse transcription. Then sequences were used to construct a phylogenetic tree to determine genetic subtypes and submitted to the Stanford drug resistance database for drug resistance analysis. Results: A total of 479 samples were successfully amplified by PCR. The HIV-1 genetic subtypes included CRF01_AE, CRF07_BC, B, CRF55_01B, CRF59_01B, CRF65_cpx, CRF103_01B, CRF67_01B, CRF68_01B and unrecognized subtype, which accounted for 43.4%, 36.3%, 6.3%, 5.9%, 0.8%, 0.8%, 0.4%, 0.4%, 0.2% and 5.5%, respectively. The distribution of genetic subtypes among provinces is statistically different (χ2=44.141, P<0.001). The overall PDR rate was 4.6% (22/479), the drug resistance rate of non-nucleoside reverse transcriptase inhibitors, nucleoside reverse transcriptase inhibitors, and protease inhibitors were 3.5% (17/479), 0.8% (4/479) and 0.2% (1/479), respectively. The PDR rate of recent infections was significantly higher than that of long-term infections (χ2=4.634, P=0.031). Conclusions: The HIV-1 genetic subtypes among MSM infected with HIV-1 from 19 cities of 6 provinces in China are diverse, and the distribution of subtypes is different among provinces. The overall PDR rate is low, while the PDR rate of recent infections was significantly higher than that of long-term infections, suggesting the surveillance of PDR in recent infections should be strengthened.
Collapse
Affiliation(s)
- R Zhang
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - T L Dong
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - W L Liang
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - Z B Cao
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - Z Xie
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - K M Liu
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - F Yu
- Danlan Beijing Media Limited, Beijing 100020, China
| | - G F Fu
- Jiangsu Provincial Center for Disease Control and Prevention,Nanjing 210009, China
| | - Y Q Zhang
- Hebei Provincial Center for Disease Control and Prevention,Shijiazhuang 050021, China
| | - G Y Wang
- Shandong Center for Disease Control and Prevention, Ji'nan 250014, China
| | - Q Q Ma
- Zhejiang Provincial Center for Disease Control and Prevention,Hangzhou 310051, China
| | - S B Wu
- Fujian Provincial Center for Disease Control and Prevention, Fuzhou 350012,China
| | - Y Li
- Guangdong Provincial Center for Disease Control and Prevention, Guangzhou 511430, China
| | - W Dong
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - Z Jiang
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - J Xu
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - Z Y Wu
- Division of HIV Prevention and Intervention, National Center for AIDS/STD Control and Prevention,Chinese Center for Disease Control and Prevention, Beijing 102206,China
| | - J Yao
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - P L Pan
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| | - M F Qiu
- National HIV Reference Laboratory, National Center for AIDS/STD Control and Prevention, Chinese Center for Disease Control and Prevention, Beijing 102206, China
| |
Collapse
|
29
|
Hicks RJ, Dromain C, de Herder WW, Costa FP, Deroose CM, Frilling A, Koumarianou A, Krenning EP, Raymond E, Bodei L, Sorbye H, Welin S, Wiedenmann B, Wild D, Howe JR, Yao J, O’Toole D, Sundin A, Prasad V. ENETS standardized (synoptic) reporting for molecular imaging studies in neuroendocrine tumours. J Neuroendocrinol 2022; 34:e13040. [PMID: 34668262 PMCID: PMC11042683 DOI: 10.1111/jne.13040] [Citation(s) in RCA: 7] [Impact Index Per Article: 3.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/14/2021] [Revised: 08/29/2021] [Accepted: 08/31/2021] [Indexed: 11/27/2022]
Abstract
The European Neuroendocrine Tumor Society (ENETS) promotes practices and procedures that aim to improve the standard of care delivered to patients diagnosed with or suspected of having neuroendocrine neoplasia (NEN). At its annual Scientific Advisory Board Meeting in 2018, experts in imaging, pathology and clinical care of patients with NEN drafted guidance for the standardised reporting of diagnostic studies critical to the diagnosis, grading, staging and treatment of NEN. These included pathology, radiology, endoscopy and molecular imaging procedures. In an iterative process, a synoptic reporting template for molecular imaging procedures was developed to guide personalised therapies. Following pilot implementation and refinement within the ENETS Center of Excellence network, harmonisation with specialist imaging societies including the Society of Nuclear Medicine, European Association of Nuclear Medicine and the International Cancer Imaging Society will be pursued.
Collapse
Affiliation(s)
- RJ Hicks
- Neuroendocrine Service, the Peter MacCallum Cancer Centre and Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, Australia
| | - C Dromain
- Lausanne University Hospital, Department of Radiology and University of Lausanne, Lausanne, Switzerland
| | - W W de Herder
- Erasmus MC, Department of Internal Medicine, Section of Endocrinology, Rotterdam, The Netherlands
| | - FP Costa
- Centro de Oncologia of Hospital Sírio Libanês, Sao Paulo, Brazil
| | - C M Deroose
- University Hospitals Leuven, Nuclear Medicine and KU Leuven, Department of Imaging and Pathology, Nuclear Medicine & Molecular Imaging, Leuven, Belgium
| | - A Frilling
- Imperial College London, Department of Surgery and Cancer, Hammersmith Hospital, London, United Kingdom
| | - A Koumarianou
- National and Kapodistrian University of Athens, Hematology Oncology Unit, 4th Department of Internal Medicine, Athens, Greece
| | - EP Krenning
- Erasmus MC, Cyclotron Rotterdam BV, Rotterdam, The Netherlands
| | - E Raymond
- Medical Oncology, Hôspital Paris Saint-Joseph, Paris, France
| | - L Bodei
- Memorial Sloan Kettering Cancer Center, Department of Radiology, Molecular Imaging and Therapy Service, New York, USA
| | - H Sorbye
- Haukeland University Hospital, Department of Oncology and Department of Clinical Science, Bergen, Norway
| | - S Welin
- Endocrine Oncology, Uppsala University Hospital, Uppsala, Sweden
| | - B Wiedenmann
- Charité Universitätsmedizin Berlin, Berlin, Germany
| | - D Wild
- University of Basel Hospital, Department of Radiology and Nuclear Medicine, Basel, Switzerland
| | - JR Howe
- Department of Surgery, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA
| | - J Yao
- University of Texas M.D. Anderson Cancer Center, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, Houston, Texas, USA
| | - D O’Toole
- St. James’s and St. Vincent’s University Hospitals & Trinity College Dublin, Dublin, Ireland
| | - A Sundin
- Department of Surgical Sciences, Uppsala University, Radiology and Molecular Imaging, Uppsala University Hospital, Uppsala, Sweden
| | - V Prasad
- Department of Nuclear Medicine, University Ulm, Ulm Germany
| |
Collapse
|
30
|
Yao J, Zhang W, Wang J, Wang K, Lv C, Zhang Z, Chen X, Chen Y, Jiang W, Niu J, Song F, Liu P, Sun D. The Status of Iodine Nutrition after Removing Iodized Salt in High Water Iodine Regions: a Cross-sectional Study in China. Biol Trace Elem Res 2022; 200:1020-1031. [PMID: 33929694 DOI: 10.1007/s12011-021-02727-w] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/05/2021] [Accepted: 04/15/2021] [Indexed: 11/29/2022]
Abstract
Currently, the removal of iodized salt is carried out in high water iodine regions. The present situation of iodine nutrition and the prevalence of thyroid diseases in such regions have not been clearly elucidated. This study aimed to figure out these problems to help render effective measures for cases of abnormal iodine nutrition status. A cross-sectional study was carried out in four areas of Jining and Heze, Shandong Province, China, with different water iodine concentrations (WIC). In total, 1344 adults were enrolled in this study, and data related to their iodine nutrition, thyroid function, and thyroid ultrasonography were collected. Subjects were grouped according to WIC, urine iodine concentration (UIC), serum iodine concentration (SIC), and combined UIC and SIC for analysis. Iodine levels were in excess in the 100 μg/L ≤ WIC < 300 μg/L and WIC ≥ 300 μg/L areas. Compared with the control WIC group (10-100 μg/L), the WIC ≥ 300 μg/L group had a higher prevalence of thyroid autoimmunity (TAI, 21.25% vs. 13.19%, P <0.05), subclinical hypothyroidism (SH, 20.20% vs. 11.96%, P < 0.05), thyroid nodules (TN, 31.75% vs. 18.71%, P < 0.05), and thyroid dysfunction (23.62% vs. 12.26%, P < 0.05). Compared with the UIC control group (100-300 μg/L), high UIC group (≥ 800 μg/L) had a higher prevalence of TN (33.75% vs. 21.14%, P < 0.05) and thyroid dysfunction (25% vs. 14.47%, P < 0.05). Next, compared with the control SIC group (50-110 μg/L), high SIC group (≥ 110 μg/L) had a higher prevalence of TAI (33.80% vs. 14.47%, P < 0.05), SH (23.94% vs. 14.30%, P < 0.05), and thyroid dysfunction (33.80% vs. 15.29%, P < 0.05). Finally, subjects with the highest UIC and the highest SIC also had a higher prevalence of TAI (25.92% vs. 10.97%, P < 0.05), SH (23.45% vs. 10.97%, P < 0.05), TN (34.56% vs. 15.85%, P < 0.05), and thyroid dysfunction (27.16% vs. 13.41%, P < 0.05) than subjects with middle iodine levels. The iodine nutrition of subjects in the WIC ≥ 300 μg/L areas was still in excess after removing iodized salt from their diets. High levels of iodine also increased the prevalence of TAI, SH, TN, and thyroid dysfunction in those areas. Simply removing iodized salt may not be sufficient for high water iodine regions.
Collapse
Affiliation(s)
- J Yao
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - W Zhang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - J Wang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - K Wang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - C Lv
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - Z Zhang
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - X Chen
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - Y Chen
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - W Jiang
- Institute of Endemic Disease Control, Jinan, Shandong Province, China
| | - J Niu
- Heze Center for Disease Control and Prevention, Heze, China
| | - F Song
- Jining Center for Disease Control and Prevention, Jining, China
| | - P Liu
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China
| | - D Sun
- Center for Endemic Disease Control, Chinese Center for Disease Control and Prevention, Harbin Medical University, Harbin, China.
| |
Collapse
|
31
|
Liu S, Chen H, Wang C, Xu Q, Feng S, Wang Y, Yao J, Zhou Q, Tong C, Yang B, Chen J, Jiang H. POS-340 MAPK1 MEDIATES HIGH GLUCOSE INDUCED RENAL TUBULAR INJURY THROUGH DISRUPTING THE INTEGRITY OF MAM. Kidney Int Rep 2022. [DOI: 10.1016/j.ekir.2022.01.361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022] Open
|
32
|
Fogarty S, Yao J, Bui J, McCusker M, Zentner D, Grigg L, Lui E, Joshi S. Obesity and Over-Indexation of Right Ventricular Volumes—Potential Implications for Timing of Pulmonary Valve Replacement in Patients With Tetralogy of Fallot. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.271] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
33
|
Fogarty S, Yao J, Bui J, McCusker M, Zentner D, Grigg L, Lui E, Joshi S. Variation in Body Surface Area Calculators Leads to Significant Changes in Indexed RV Volumes in Tetralogy of Fallot Patients. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.304] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
34
|
Yao J, Wong J, Joshi S. Apical Hypertrophic Cardiomyopathy Masquerading as Takotsubo Cardiomyopathy: The Importance of Serial Echocardiography. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.219] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
35
|
Wang B, Yao J, Sethwala A, Stevenson I. Association Between Pocket Haematoma Formation and Various Antiplatelet Therapies Following Cardiac Device Procedures. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.146] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
36
|
Yao J, Duong V, Thakkar H, Wilson W, Rangamuwa K. Inferior STEMI and Cardiac Arrest Due To Likely Air Embolism During Transbronchial Lung Biopsy. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.596] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
37
|
Wang B, Wong J, Yao J, Grigg L, Wilson W. Early inflammatory reaction and thrombus formation post Gore® Septal Occluder Device insertion for an atrial septal defect. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.675] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
|
38
|
Yao J, Ward-Ambler E, Wong J, Kalman J. Polymorphic Ventricular Tachycardia Following Valsalva Manoeuvre Used to Terminate Supraventricular Tachycardia. Heart Lung Circ 2022. [DOI: 10.1016/j.hlc.2022.06.183] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/16/2022]
|
39
|
Wei X, Fang C, Gong B, Yao J, Qian J, Lin Y. Viscoelasticity of 3D actin networks dictated by the mechanochemical characteristics of cross-linkers. Soft Matter 2021; 17:10177-10185. [PMID: 33646227 DOI: 10.1039/d0sm01558j] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/12/2023]
Abstract
In this study, we report a computational investigation on how the mechanochemical characteristics of crosslinking molecules influence the viscoelasticity of three dimensional F-actin networks, an issue of key interest in analyzing the behavior of living cells and biological gels. In particular, it was found that the continuous breakage and rebinding of cross-linkers result in a locally peaked loss modulus in the rheology spectrum of the network, reflecting the fact that maximum energy dissipation is achieved when the driving frequency of the applied oscillating shear becomes comparable to the dissociation/association rate of crosslinking molecules. In addition, we showed that when subjected to constant rate of shear, an actin network can exhibit either strain hardening or softening depending on the ratio between the loading rate and unbinding speed of cross-linkers. A criterion for predicting the transition from softening to hardening was also obtained, in agreement with recent experiments. Finally, significant structural evolution was found to occur in random networks undergoing mechanical "training" (i.e. under a constant applied shear stress over a period of time), eventually leading to a pronounced anisotropic response of the network afterward which again is consistent with experimental observations.
Collapse
Affiliation(s)
- X Wei
- Department of Mechanical Engineering, The University of Hong Kong, Hong Kong, China.
- HKU-Shenzhen Institute of Research and Innovation (HKU-SIRI), Guangdong, China
| | - C Fang
- Department of Mechanical Engineering, The University of Hong Kong, Hong Kong, China.
- HKU-Shenzhen Institute of Research and Innovation (HKU-SIRI), Guangdong, China
| | - B Gong
- Department of Engineering Mechanics, Key Laboratory of Soft Machines and Smart Devices of Zhejiang Province, Zhejiang University, Hangzhou, Zhejiang, China.
| | - J Yao
- Department of Mechanical Engineering, The University of Hong Kong, Hong Kong, China.
- HKU-Shenzhen Institute of Research and Innovation (HKU-SIRI), Guangdong, China
| | - J Qian
- Department of Engineering Mechanics, Key Laboratory of Soft Machines and Smart Devices of Zhejiang Province, Zhejiang University, Hangzhou, Zhejiang, China.
| | - Y Lin
- Department of Mechanical Engineering, The University of Hong Kong, Hong Kong, China.
- HKU-Shenzhen Institute of Research and Innovation (HKU-SIRI), Guangdong, China
| |
Collapse
|
40
|
Chang L, Zhang X, Zhang YP, Qin DY, Liu WJ, Chai B, Yao J. [PD-1 is associated with CD8(+)T lymphocyte dysfunction in patients with acute and chronic liver failure]. Zhonghua Gan Zang Bing Za Zhi 2021; 29:1101-1105. [PMID: 34933430 DOI: 10.3760/cma.j.cn501113-20200204-00028] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/14/2023]
Abstract
Objective: To explore whether peripheral blood CD8(+)T lymphocyte dysfunction is correlated with the programmed death receptor-1 (PD-1) expression in patients with acute-on-chronic liver failure (HBV-ACLF). Methods: Peripheral blood mononuclear cells (PBMC) were collected from patients with HBV-ACLF and healthy controls. CD8(+)T lymphocytes number and PD-1 expression condition in CD8(+)T lymphocytes were detected by flow cytometry. CD8(+)T lymphocytes isolated from peripheral blood of HBV-ACLF patients were further cultured in vitro. One group was added with PD-L1-IgG fusion protein (ACLF+PD-1 group), and the other group was added with IgG fusion protein (ACLF group). Proliferation ability (ki67), cell viability (CD69), and secretion ability of effector cytokines (IL-2, IFN-γ, TNF-α) were analyzed. Results: 30 cases with HBV-ACLF and healthy controls were enrolled. CD8(+)T lymphocytes absolute number was significantly lower in the peripheral blood of patients with ACLF group (333.88 ± 147.74)/μl than healthy controls (872.50 ± 206.64)/μl (P < 0.001). PD-1 expression in peripheral blood CD8(+)T lymphocytes were significantly increased in ACLF group (13.33% ± 2.52%), (P = 0.027) than healthy controls (7.02% ± 2.12%). In in vitro culture, compared with healthy controls, the peripheral blood CD8(+)T lymphocytes cell viability (CD69), proliferation ability (ki67) (all P < 0.001), and the level of cytokine production (IL-2, IFN-γ, TNF-α) (all P < 0.05) were equally weakened in patients with ACLF group. Compared with ACLF group, CD8(+)T cell viability (CD69), proliferation ability (KI67) (all P < 0.05), and the level of cytokine production were weakened in ACLF+PD-1 group (all P < 0.05). Conclusion: HBV-ACLF patients have CD8(+)T lymphocyte dysfunction. Therefore, PD-1 may have correlation in the regulation of CD8(+)T lymphocyte dysfunction in ACLF patients.
Collapse
Affiliation(s)
- L Chang
- Department of Gastroenterology, Shanxi Baiqiuen hospital, Taiyuan 030032, China
| | - X Zhang
- Department of ultrasound Shanxi Children's Hospital, Taiyuan 030000, China
| | - Y P Zhang
- Department of Gastroenterology, Shanxi Baiqiuen hospital, Taiyuan 030032, China
| | - D Y Qin
- Department of Gastroenterology, Shanxi Baiqiuen hospital, Taiyuan 030032, China
| | - W J Liu
- Department of Gastroenterology, Shanxi Baiqiuen hospital, Taiyuan 030032, China
| | - B Chai
- Department of Gastroenterology, Shanxi Baiqiuen hospital, Taiyuan 030032, China
| | - J Yao
- Department of Gastroenterology, Shanxi Baiqiuen hospital, Taiyuan 030032, China Postdoctoral Workstation, The First Affiliated Hospital of Shanxi Medical University, Taiyuan 030031, China
| |
Collapse
|
41
|
Hagiwara A, Bydder M, Oughourlian TC, Yao J, Salamon N, Jahan R, Villablanca JP, Enzmann DR, Ellingson BM. Sodium MR Neuroimaging. AJNR Am J Neuroradiol 2021; 42:1920-1926. [PMID: 34446457 PMCID: PMC8583254 DOI: 10.3174/ajnr.a7261] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/12/2021] [Accepted: 05/28/2021] [Indexed: 12/26/2022]
Abstract
Sodium MR imaging has the potential to complement routine proton MR imaging examinations with the goal of improving diagnosis, disease characterization, and clinical monitoring in neurologic diseases. In the past, the utility and exploration of sodium MR imaging as a valuable clinical tool have been limited due to the extremely low MR signal, but with recent improvements in imaging techniques and hardware, sodium MR imaging is on the verge of becoming clinically realistic for conditions that include brain tumors, ischemic stroke, and epilepsy. In this review, we briefly describe the fundamental physics of sodium MR imaging tailored to the neuroradiologist, focusing on the basics necessary to understand factors that play into making sodium MR imaging feasible for clinical settings and describing current controversies in the field. We will also discuss the current state of the field and the potential future clinical uses of sodium MR imaging in the diagnosis, phenotyping, and therapeutic monitoring in neurologic diseases.
Collapse
Affiliation(s)
- A Hagiwara
- From the UCLA Brain Tumor Imaging Laboratory (A.H., M.B., T.C.O., J.Y., B.M.E.), Center for Computer Vision and Imaging Biomarkers
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
| | - M Bydder
- From the UCLA Brain Tumor Imaging Laboratory (A.H., M.B., T.C.O., J.Y., B.M.E.), Center for Computer Vision and Imaging Biomarkers
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
| | - T C Oughourlian
- From the UCLA Brain Tumor Imaging Laboratory (A.H., M.B., T.C.O., J.Y., B.M.E.), Center for Computer Vision and Imaging Biomarkers
- Neuroscience Interdepartmental Program (T.C.O., B.M.E.)
| | - J Yao
- From the UCLA Brain Tumor Imaging Laboratory (A.H., M.B., T.C.O., J.Y., B.M.E.), Center for Computer Vision and Imaging Biomarkers
- Department of Bioengineering (J.Y., B.M.E.), Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, California
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
| | - N Salamon
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
| | - R Jahan
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
| | - J P Villablanca
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
| | - D R Enzmann
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
| | - B M Ellingson
- From the UCLA Brain Tumor Imaging Laboratory (A.H., M.B., T.C.O., J.Y., B.M.E.), Center for Computer Vision and Imaging Biomarkers
- Department of Bioengineering (J.Y., B.M.E.), Henry Samueli School of Engineering and Applied Science, University of California Los Angeles, Los Angeles, California
- Department of Radiological Sciences (A.H., M.B., J.Y., N.S., R.J., J.P.V., D.R.E., B.M.E.)
- Neuroscience Interdepartmental Program (T.C.O., B.M.E.)
- Department of Psychiatry and Biobehavioral Sciences (B.M.E.), David Geffen School of Medicine, University of California, Los Angeles, Los Angeles, California
| |
Collapse
|
42
|
Zhang Y, Yao J, Quan Y, Wang J, Xing Y, Zhou A. [Treatment response to Conbercept of different types of diabetic macular edema classified based on optical coherence tomography]. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41:1501-1508. [PMID: 34755665 DOI: 10.12122/j.issn.1673-4254.2021.10.08] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
Abstract
OBJECTIVE To compare different types of diabetic macular edema (DME) classified based on optical coherence tomography (OCT) for their responses to Conbercept injection and analyze the factors that affect the treatment responses. METHODS We retrospectively analyzed the clinical data of 65 patients (76 eyes) with DME diagnosed and treated with intravitreal injection of Conbercept (1+PRN) in our hospital from February, 2019 to February, 2021. According to OCT findings, DME in these patients was classified into cystic macular edema (CME; 28 eyes), serous retinal detachment (SRD; 33 eyes), and diffuse retinal thickening (DRT; 15 eyes). The best corrected visual acuity (BCVA) and central retinal thickness (CRT) were measured before and at 3 months after the first treatment. The baseline OCT characteristics of different types of DME were compared, and the correlation of these OCT characteristics with the treatment response to Conbercept was analyzed. RESULTS All the patients showed significant improvement of the BCVA 3 months after the treatment (P < 0.05). For all the 3 types of DME, the CRT at 3 months after the first treatment was significantly reduced as compared to the baseline (P < 0.05). The number of hyperreflective foci (HF) in the outer retina and the proportion of ellipsoid zone (EZ) interruption were the greatest in SRD group (P < 0.05). The baseline outer retinal HF was significantly correlated with the baseline CRT, CRT changes and CRT after treatment (all P < 0.05). The patients with baseline outer limiting membrane (ELM)/ EZ disruption had poorer baseline BCVA, greater baseline CRT, greater variation of CRT and poorer BCVA at 3 months after treatment (all P < 0.05). CONCLUSION For all the 3 types of DME, treatment with intravitreal injection of Conbercept can significantly improve the BCVA and CRT of the patients. DME of the SRD type has the best morphological response to Conbercept, while the DRT type has a relatively poor response. A greater number of HF at baseline may indicate a better morphological response to Conbercept treatment, and baseline ELM/EZ disruption may suggest a poor visual prognosis at 3 months after treatment.
Collapse
Affiliation(s)
- Y Zhang
- Department of Ophthalmology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - J Yao
- Department of Ophthalmology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Y Quan
- Department of Ophthalmology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - J Wang
- Department of Ophthalmology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - Y Xing
- Department of Ophthalmology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| | - A Zhou
- Department of Ophthalmology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China
| |
Collapse
|
43
|
Xu RH, Wang F, Cui C, Yao J, Zhang Y, Wang G, Feng J, Yang S, Fan Y, Shi J, Zhang X, Shen L, Shu Y, Wang C, Dai T, Mao T, Chen L, Guo Z, Liu B, Pan H. 1373MO JUPITER-06: A randomized, double-blind, phase III study of toripalimab versus placebo in combination with first-line chemotherapy for treatment naive advanced or metastatic esophageal squamous cell carcinoma (ESCC). Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.08.1482] [Citation(s) in RCA: 15] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
44
|
Yang Y, Wu J, Wang X, Yao J, Lao KS, Xu Y, Hu Y, Pan Y, Feng Y, Shi S, Zhang J, Qiao Y, Li Q, Ye D, Wang Y. P–389 The relationship between serum hormone profiles and missed abortion in humans. Hum Reprod 2021. [DOI: 10.1093/humrep/deab130.388] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
Abstract
Abstract
Study question
Are circulating profiles of metabolic-related hormones also associated with the missed abortion (MA) in humans?
Summary answer
Serum levels of fatty acid-binding protein–4 (FABP4) and fibroblast growth factor 21 (FGF21) are positively associated with MA.
What is known already
A cluster of endocrine hormones, including FABP4, FGF21, adiponectin, lipocalin–2 (LCN2), exhibit pleiotropic effects on regulating systematic metabolism. Serum levels of them are associated with gestational obesity and diabetes and affect pregnancy outcomes, however, the relationship between their circulating profiles and MA is under-investigated.
Study design, size, duration
78 patients with MA and 86 healthy pregnant subjects matching on maternal age and body mass index (BMI) were nested from a prospective cohort in the Chinese population.
Participants/materials, setting, methods
Fasting serum samples from all participants were collected to test their serum levels of FGF21, FABP4, adiponectin, and LCN2 by enzyme-linked immunosorbent assay method (ELISA).
Main results and the role of chance
There were no significant differences in circulating profiles of adiponectin and LCN2 between MA patients and healthy pregnant subjects. By contrast, circulating levels of FGF21 and FABP4 were significantly and independently elevated in patients with MA relative to control cases even after adjusting confounding factors (for FGF21: MA: 28.96 ± 2.17 ng/ml; HP: 19.18 ± 1.12 ng/ml, P < 0.001, for FABP4: MA: 152.50 ± 9.31 pg/ml; HP: 90.86 ± 4.14 pg/ml, P < 0.001). Linear regression analysis showed, FGF21 raised every 10 pg/ml contributed to a 24% (95% CI: 15% - 34%) increase in the risk of MA, whereas the OR of FABP4 for the risk of MA was 1.052 (95% CI: 1.022 –1.088). Furthermore, using serum FGF21 level or FABP4 levels discriminated MA from healthy controls with an area under the operating characteristic’s curve (AUROC) of 0.81 (95% CI 0.76–0.92) and 0.70 (95% CI 0.62 - 0.78), respectively.
Limitations, reasons for caution
The study is limited by the sample size. In addition, our results were based-on Chinese population, whether it could be observed in other ethics group remain to be investigated. Meanwhile, the cause-effect relationship between increased serum FGF21 level and MA remains to be explored.
Wider implications of the findings: Our data would suggest that serum levels of FGF21 and FABP4 are associated with MA. Moreover, circulating FGF21 levels may serve as a potential diagnostic biomarker for the recognition of M.
Trial registration number
IRB Ref. No.: KY201913
Collapse
Affiliation(s)
- Y Yang
- Shaanxi University of Chinese Medicine, The Second Clinical Medical College, Xianyang, China
| | - J Wu
- The University of Hong Kong, State Key Laboratory of Pharmaceutical Biotechnology, Hong Kong SAR, China
| | - X Wang
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - J Yao
- Guangdong Pharmaceutical University, Guangdong Research Center of Metabolic Diseases of Integrated Western and Chinese Medicine, Guangzhou, China
| | - K S Lao
- The University of Hong Kong, Centre for Safe Medication Practice and Research, Hong Kong SAR, China
| | - Y Xu
- Guangdong Pharmaceutical University, The First Affiliated Hospital/School of Clinical Medicine, Guangzhou, China
| | - Y Hu
- The University of Hong Kong, State Key Laboratory of Pharmaceutical Biotechnology, Hong Kong SAR, China
| | - Y Pan
- Shenzhen University, School of Biomedicine Science, Shenzhen, China
| | - Y Feng
- Shaanxi University of Chinese Medicine, The Second Clinical Medical College, Xianyang, China
| | - S Shi
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - J Zhang
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - Y Qiao
- Shaanxi University of Chinese Medicine, Department of Obstetrics and Gynecology, Xianyang, China
| | - Q Li
- Shaanxi University of Chinese Medicine, The Second Clinical Medical College, Xianyang, China
| | - D Ye
- Guangdong Pharmaceutical University, Guangdong Research Center of Metabolic Diseases of Integrated Western and Chinese Medicine, Guangzhou, China
| | - Y Wang
- The University of Hong Kong, State Key Laboratory of Pharmaceutical Biotechnology, Hong Kong SAR, China
| |
Collapse
|
45
|
Strosberg J, Caplin M, Kunz P, Ruszniewski P, Bodei L, Hendifar A, Mittra E, Wolin E, Yao J, Pavel M, Grande Pulido E, Van Cutsem E, Seregni E, Duarte H, Gericke G, Bartalotta A, Demange A, Mutevelic S, Krenning E. O-2 Overall survival and long-term safety data from the NETTER-1 trial: 177-Lu-Dotatate vs. high-dose octreotide in patients with progressive midgut NETs. Ann Oncol 2021. [DOI: 10.1016/j.annonc.2021.05.006] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
46
|
Wang B, Yao J, Yao X, Lao J, Liu D, Chen C, Lu Y. [Swertiamarin alleviates diabetic peripheral neuropathy in rats by suppressing NOXS/ ROS/NLRP3 signal pathway]. Nan Fang Yi Ke Da Xue Xue Bao 2021; 41:937-941. [PMID: 34238748 PMCID: PMC8267977 DOI: 10.12122/j.issn.1673-4254.2021.06.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 03/18/2023]
Abstract
OBJECTIVE To observe the therapeutic effect of swertiamarin on diabetic peripheral neuropathy (DPN) in rats and explore the molecular mechanism in light of the NOXS/ROS/NLRP3 signal pathway. OBJECTIVE Thirty-two SD rats were randomly divided into control group, DPN model group (treated with saline), swertiamarin (5 mg/kg) treatment group and NOXS inhibitor (10 mL/kg DPI) treatment group. Rat models of DPN were established in the latter 3 groups by intraperitoneal injections of STZ, and the treatments were administered on days 1, 7 and 14 after modeling. Tactile hypersensitivity of the rats was evaluated 30 min after the treatment. The expressions of NOXS, ROS, NLRP3 and inflammatory factors in the spinal cord tissue were detected using ELISA, and the protein expressions of NOXS, ROS, and NLRP3 were also detected with Western blotting. OBJECTIVE Compared with those in the control group, the rats in DPN group showed significant hyperalgesia (P < 0.001), increased expressions of TNF-α (P < 0.001) and IL-6 (P < 0.001), decreased expressions of TGF-β (P < 0.001), and increased expressions of NOXS/ROS/NLRP3 signal pathway (P < 0.001). Compared with those in DPN model group, the rats with swertiamarin treatment showed improved hyperalgesia (P < 0.001), decreased expressions of TNF-α (P=0.03) and IL-6 (P=0.002), increased expressions of TGF-β (P=0.04), and decreased expressions of NOXS (P < 0.001), ROS (P < 0.001) and NLRP3 (P=0.002). Treatment with swertiamarin and the NOXS inhibitor produced similar effects on the expressions of the inflammatory factors in the rat models (P>0.05). OBJECTIVE DPN effectively relieves hyperalgesia in rat models of DPN by restoring the balance in the expressions of the inflammatory factors by suppressing NOXs/ROS/NLRP3 signaling pathway.
Collapse
Affiliation(s)
- B Wang
- Department of Anesthesiology, Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou 510130, China
| | - J Yao
- Department of Gastroenterology, Sixth Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510655, China
| | - X Yao
- Department of Anesthesiology, Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou 510130, China
| | - J Lao
- Department of Anesthesiology, Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou 510130, China
| | - D Liu
- Department of Anesthesiology, Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou 510130, China
| | - C Chen
- Department of Anesthesiology, Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou 510130, China
| | - Y Lu
- Department of Anesthesiology, Affiliated TCM Hospital of Guangzhou Medical University, Guangzhou 510130, China
| |
Collapse
|
47
|
Chen J, Wang MW, Xu JJ, Wu XY, Yao J. Gelatin methacryloyl hydrogel eye pad loaded with amniotic extract prevents symblepharon in rabbit eyes. Eur Rev Med Pharmacol Sci 2021; 24:10134-10142. [PMID: 33090421 DOI: 10.26355/eurrev_202010_23233] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The aim was to evaluate the ability of gelatin methacryloyl (GelMA) hydrogel eye pads loaded with amniotic extract to prevent symblepharon in rabbits. MATERIALS AND METHODS Forty-eight rabbits were divided into 3 groups. After ocular alkali burn, Group A (n=16) was treated with amniotic extract-loaded hydrogel eye pads placed in the conjunctival sac, Group B (n=16) was treated with amniotic membrane transplantation, and Group C (n=16) received no treatment. At 1, 2, 3, and 4 weeks post-injury, 4 rabbits from each group were selected to evaluate for symblepharon, determine epithelial healing rate and corneal neovascularization, conduct histopathology, and to quantify the expression of TGF-β1. RESULTS At 1 week post-injury, the epithelial healing rate in Groups A and B was higher than Group C (p=0.002, 0.001, respectively). At 2 weeks, corneal neovascularization in Group B was less than Group C (p=0.004). At 3 and 4 weeks, no symblepharon has been found in Group A, but it was found in some eyes in Group B and C (p=0.009, 0.013). Further, the expression of TGF-β1 in Group A was lower than in Group B and C (p<0.001). H&E staining showed that the controls in Group C had more edema and inflammatory cell infiltration in the first 2 weeks, relative to Groups A and B. At 4 weeks, Masson's Trichrome staining showed that fibers were most regularly aligned in Group A and that immuno-histochemical staining found that proliferating cell nuclear antigen was highest expressed in Group C. CONCLUSIONS Treatment with GelMA hydrogel eye pads loaded with amniotic extract shortly after chemical injury prevented symblepharon in rabbits.
Collapse
Affiliation(s)
- J Chen
- Eye Hospital, Nanjing Medical University, Nanjing, China.
| | | | | | | | | |
Collapse
|
48
|
Luan PB, Sun XM, Yao J. LINC00355 inhibits apoptosis and promotes proliferation of gastric cancer cells by regulating Wnt/β-catenin signaling pathway. Eur Rev Med Pharmacol Sci 2021; 24:8377-8383. [PMID: 32894544 DOI: 10.26355/eurrev_202008_22634] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE To study the expression and biological functions of long intergenic non-protein coding ribonucleic acid 00355 (LINC00355) in gastric cancer (GC), and to explore its potential mechanism of action. PATIENTS AND METHODS The relative expression level of LINC00355 in 48 cases of GC tissues, the corresponding paracancerous tissues, and GC cells was determined using quantitative reverse transcription-polymerase chain reaction (qRT-PCR), and the interference efficiency of small interfering (si)-LINC00355 was detected via qRT-PCR. After knock-down of LINC00355, methyl thiazolyl tetrazolium (MTT) and 5-ethynyl-2'-deoxyuridine (EdU) assays were performed to detect the changes in the proliferation ability of GC cells, and the changes in the GC cell cycle distribution and apoptosis rate were examined by flow cytometry. Besides, Western blotting was conducted to verify the changes in the downstream signaling pathway of LINC00355. RESULTS Among 48 cases of GC tissues, there were 42 (87.5%) cases of LINC00355 expression up-regulation, and 6 (12.5%) cases of LINC00355 expression down-regulation. The qRT-PCR results revealed that the expression of LINC00355 was raised in 4 kinds of GC cells. After interference with LINC00355 expression, the MTT assay results indicated that the cell proliferation ability was inhibited, consistent with the EdU assay results. After LINC00355 was knocked down in GC cells, GC cells in experiment group had a higher apoptosis rate than those in si-NC group and arrested in the gap 0 (G0)/G1 phase. Moreover, it was found through Western blotting that the expressions of the molecular markers in the downstream wingless-INT (Wnt)/β-catenin signaling pathway were downregulated after interference with the expression of LINC00355. CONCLUSIONS LINC0035 exhibits an up-regulated expression in GC and regulates the Wnt/β-catenin signaling pathway to promote proliferation and inhibit apoptosis.
Collapse
Affiliation(s)
- P-B Luan
- Department of General Surgery, Yantaishan Hospital, Yantai, China.
| | | | | |
Collapse
|
49
|
Xu W, Ma X, Yao J, Wang D, Li W, Liu L, Shao L, Wang Y. Increasing coenzyme Q 10 yield from Rhodopseudomonas palustris by expressing rate-limiting enzymes and blocking carotenoid and hopanoid pathways. Lett Appl Microbiol 2021; 73:88-95. [PMID: 33783839 DOI: 10.1111/lam.13479] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/28/2020] [Revised: 03/24/2021] [Accepted: 03/25/2021] [Indexed: 11/29/2022]
Abstract
Coenzyme Q10 (CoQ10 ), a strong antioxidant, is used extensively in food, cosmetic and medicine industries. A natural producer, Rhodopseudomonas palustris, was engineered to overproduce CoQ10 . For increasing the CoQ10 content, crtB gene was deleted to block the carotenoid pathway. crtB gene deletion led to 33% improvement of CoQ10 content over the wild type strain. However, it was found that the yield of hopanoids was also increased by competing for the precursors from carotenoid pathway with CoQ10 pathway. To further increase the CoQ10 content, hopanoid pathway was blocked by deleting shc gene, resulting in R. palustris [Δshc, ΔcrtB] to produce 4·7 mg g-1 DCW CoQ10 , which was 1·2 times higher than the CoQ10 content in the wild type strain. The common strategy of co-expression of rate-limiting enzymes (DXS, DPS and UbiA) was combined with the pathway blocking method resulted in 8·2 mg g-1 DCW of CoQ10 , which was 2·9 times higher than that of wild type strain. The results suggested a synergistic effect among different metabolic engineering strategies. This study demonstrates the potential of R. palustris for CoQ10 production and provides viable strategies to increase CoQ10 titer.
Collapse
Affiliation(s)
- W Xu
- The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi, China
| | - X Ma
- The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi, China
| | - J Yao
- The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi, China
| | - D Wang
- Department of Prosthodontics, School of Stomatology, Xi'an Medical University, Xi'an, Shaanxi, China
| | - W Li
- The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi, China
| | - Li Liu
- The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi, China
| | - L Shao
- The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi, China
| | - Y Wang
- The Xi'an key Laboratory of Pathogenic Microorganism and Tumor Immunity, Xi'an Medical University, Xi'an, Shaanxi, China
| |
Collapse
|
50
|
Luan PB, Jia XZ, Yao J. MiR-769-5p functions as an oncogene by down-regulating RYBP expression in gastric cancer. Eur Rev Med Pharmacol Sci 2021; 24:6699-6706. [PMID: 32633360 DOI: 10.26355/eurrev_202006_21657] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The purpose of this study was to detect the relative expression level of micro-ribonucleic acid (miR)-769-5p in gastric cancer (GC) tissues and cells, and to investigate the clinical significance, biological function, and mechanism of miR-769-5p in GC. PATIENTS AND METHODS The relative expression level in 62 cases of GC tissues and paracancerous tissues was detected by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). The correlation between miR-769-5p expression and clinicopathological characteristics of GC patients was analyzed by Chi-square test. Besides, the relative expression level of miR-769-5p in GC cells and the interference efficiency of si-miR-769-5p were detected by qRT-PCR, and the biological function of miR-769-5p was studied by in vitro experiments [Thiazolyl Blue Tetrazolium Bromide (MTT), flow cytometry, 5-ethynyl-2'-deoxyuridine (EdU)]. Next, the effect of miR-769-5p on the tumorigenicity of GC cells in vivo was investigated by nude mouse tumorigenicity assay. Moreover, the downstream target genes of miR-769-5p were predicted by bioinformatics. Finally, qRT-PCR and Western blotting were used to screen the downstream target genes. RESULTS In the 62 cases of GC tissues, the expression of miR-769-5p was upregulated in 48 cases. MiR-769-5p was divided into high-expression group and low-expression group. Chi-square analysis showed that the high expression of miR-769-5p was positively correlated with tumor-node-metastasis (TNM) stage (p=0.005), lymph node metastasis (p=0.010), and infiltration depth (p=0.011) in patients with GC. The results of qRT-PCR indicated that the expression of miR-769-5p was upregulated in GC cells. In vitro experiments (MTT, flow cytometry, EdU) results showed that after interfering in the expression of miR-769-5p, the proliferation ability of GC cells was decreased, and apoptosis was increased. Furthermore, the results of in vivo experiments manifested that the tumorigenic ability of GC cells declined after interference in the expression of miR-769-5p. Finally, the results of qRT-PCR and Western blotting revealed that the expression of RING1 and YY1-binding protein (RYBP) was regulated by miR-769-5p. CONCLUSIONS The expression of miR-769-5p is upregulated in GC and positively correlated with TNM stage in GC patients. By regulating the expression of RYBP, the proliferation of GC cells was promoted, and the apoptosis was inhibited.
Collapse
Affiliation(s)
- P-B Luan
- Department of General Surgery, Yantaishan Hospital, Yantai, China.
| | | | | |
Collapse
|